k yevkhtm form ktable contents united states securities exchange commission washington dc annual report pursuant section securities exchange act fiscal year ended december oo transition report pursuant section securities exchange act transition period commission file number scheringplough corporation exact name registrant specified charter new jersey state jurisdiction irs employer incorporation organization identification galloping hill road kenilworth nj address principal executive offices zip code registrants telephone number including area code securities registered pursuant section b act title class name exchange registered common shares par value new york stock exchange mandatory convertible preferred stock new york stock exchange securities registered pursuant section g act none indicate check mark registrant wellknown seasoned issuer defined rule securities act yes indicate check mark registrant required file reports pursuant section section act yes indicate check mark whether registrant filed reports required filed section securities exchange act preceding months shorter period registrant required file reports subject filing requirements past days yes indicate check mark disclosure delinquent filers pursuant item regulation sk chapter contained herein contained best registrants knowledge definitive proxy information statements incorporated reference part iii amendment indicate check mark whether registrant large accelerated filer accelerated filer nonaccelerated filer smaller reporting company see definitions large accelerated filer accelerated filer smaller reporting company rule b exchange act check one large accelerated filer accelerated filer nonaccelerated filer smaller reporting company check smaller reporting company indicate check mark whether registrant shell company defined rule b act yes state aggregate market value voting nonvoting common equity held nonaffiliates computed reference price common equity last sold average bid asked price common equity june last business day registrants recently completed second fiscal quarter common shares outstanding january part documents incorporated refe rence incorporated scheringplough corporations proxy statement part iii annual meeting shareholders filed within days close registrants fiscal year proxy statementtable contents p age part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report internal control financial reporting item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accounting fees services part iv item exhibits financial statement schedules signatures exd stock incentive plan exexv form employment agreement exk savings advantage plan exl supplemental executive retirement plan exm retirement benefits equalization plan ex computation ratio earnings fixed charges ex subsidiaries ex consent independent registered public accounting firm ex independent auditors 's consent ex power attorney ex certification ex certification ex certifcation ex certification table contents part item business overview business scheringplough refers scheringplough corporation subsidiaries except otherwise indicated context schering corporation predecessor company incorporated new york new jersey trademarks indicated capital letters k property licensed promoted distributed scheringplough corporation subsidiaries related companies scheringplough innovationdriven sciencecentered global health care company biopharmaceutical research collaborations partners scheringplough creates therapies help save improve lives around world scheringplough applies research development platform prescription pharmaceuticals animal health consumer health care products scheringploughs vision earn trust every day doctors patients customers shareholders employees stakeholders scheringplough based kenilworth nj web site wwwscheringploughcom april board directors recruited fred hassan join scheringplough new chairman board chief executive officer support board soon arrived hassan installed new senior executive management team initiated strategic plan goal stabilizing repairing turning around scheringplough order build longterm shareholder value strategic plan action agenda six eightyear fivephase plan five years since hassan new management team arrived scheringplough made substantial progress fourth phase action agenda build base scheringplough grew broadened base marketed products expanded latestage research development project pipeline made substantial progress integration organon biosciences nv obs purchased akzo nobel late acquisition transformative giving scheringplough key new pipeline projects including asenapine schizophrenia bipolar disease sugammadex reverse deep anesthesia key products two new therapeutic areas womens health central nervous system position leader animal health combining scheringplough animal health intervet leadership position animal vaccines intervet earlystage innovation capabilities human vaccines nobilon additional stateoftheart biologics capabilities substantial expansion companys geographic footprint significant talent including key research development functions strength gained progress action agenda key scheringplough period challenge pharmaceutical industry particularly us general economy addition scheringplough faced particular challenges cholesterol products zetia vytorin particularly us discussed item legal proceedings spite challenges scheringplough delivered strong operational performance stock price suffered significant pressure productivity transformation program announced april facilitated scheringploughs achievements goal program includes ongoing integration obs create leaner stronger company support scheringploughs goal building longterm high performance despite current challenging pharmaceutical industry environment particular challenges facing schering plough program targets savings billion annualized basis designed reduce avoid costs increasing productivity total targeted savings approximately billion table contents anticipated accomplished end balance achieved targeted savings envisioned program include resulting previously announced obs integration synergies beyond program scheringplough anticipates investing new highpriority clinical trials pursuit strategic opportunities including product launches anticipates natural cost growth environment continues challenging companies geographies part due uncertainty stock markets current credit conditions financial markets pressures us pharmaceutical market include uncertainty regulatory process approving new drugs new indications reviewing labeling indications marketed products assessing information risks associated drugs human health involved always balance quest new innovation particularly address urgent unmet medical needs desire minimize risks currently balance strongly skewed toward risk minimization us resulting longer delays approving products greater costs clinical trials postmarketing trials increased scrutiny patients prescribers regulatory agencies also media many scheringploughs pharmaceutical products subject increasingly competitive pricing certain intermediaries including managed care groups institutions government agencies seek price discounts international markets scheringplough operates environment governmentmandated costcontainment programs also pricing sales marketing programs arrangements related business practices scheringplough participants health care industry continued scrutiny federal state regulatory investigative prosecutorial administrative entities segment information scheringplough three reportable segments prescription pharmaceuticals animal health consumer health care segment sales profitloss data follow consistent scheringploughs current management reporting structure prescription pharmaceuticals prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products within prescription pharmaceuticals segment scheringplough broad range research projects marketed products six therapeutic areas cardiovascular central nervous system immunology infectious disease oncology respiratory womens health prescription pharmaceuticals segment also includes nobilon human vaccine development unit diosynth thirdparty manufacturing unit marketed products include following cardiovascular disease vytorin cholesterollowering tablet combining dual action zetia merck co incs merck statin zocor simvastatin zetia novel cholesterolabsorption inhibitor discovered scheringplough scientists use monotherapy combination either statins fenofibrate lower cholesterol integrilin injection platelet receptor gp iibiiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention us well prevention early myocardial infarction patients acute coronary syndrome countries orgaran nonheparin antithrombotic central nervous system remeron antidepressant esmeronzemuron muscle relaxant used surgical procedures subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone marketed scheringplough certain countries outside us treatment opiate addiction norcuron muscle relaxant bridion sugammadex anesthesia reversal agent launched european union eu countries us review immunology infectious disease remicade antitnf antibody marketed scheringplough outside united states japan certain asian markets treatment inflammatory diseases rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis pegintron powder injection pegylated interferon product chronic hepatitis c rebetol capsules use combination pegintron intron table contents treating hepatitis c avelox scheringplough markets us broadspectrum fluoroquinolone antibiotic certain respiratory skin infections noxafil oral suspension prophylaxis prevention invasive fungal infections highrisk patients treatment oropharyngeal candidiasis also approved treatment invasive fungal infections markets outside us oncology temodartemodal certain types brain tumors including newly diagnosed glioblastoma multiforme caelyx longcirculating pegylated liposomal formulation cancer drug doxorubicin marketed scheringplough outside us treatment certain ovarian cancers kaposis sarcoma metastatic breast cancer intron injection marketed chronic hepatitis b c numerous anticancer indications worldwide including adjuvant therapy malignant melanoma respiratory nasonex oncedaily nasalinhaled steroid nasal allergy symptoms including congestion treatment nasal polyps patients years age older clarinexaeriusclaritin rx nonsedating antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist marketed scheringplough us maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exercise induced bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil hfa albuterol inhalation aerosol relief bronchospasm patients years older womens health follistimpuregon fertility treatment nuvaring vaginal contraceptive ring livial menopausal therapy marvelondesogen lowdose combined oral contraceptive mercilon lowdose combined oral contraceptive cerazette progestin oral contraceptive implanon singlerod subdermal contraceptive implant animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal marketed products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory trimerit data management tool cattle estrumate treatment fertility disorders cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor improve production efficiencies beef cattle mpac swine pneumonia vaccine pg stimulate fertility swine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines poultry companion animal products nobivaccontinuum vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals scaliborexspot protecting bites fleas ticks mosquitoes sandflies homeagain proactive us pet recovery network aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish table contents consumer health care consumer health care segment develops manufactures markets overthecounter otc foot care sun care products principal products segment include overthecounter products claritin nonsedating antihistamines miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray correctol laxative tablets foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils lipprotection products sunless tanning products solarcaine sunburn relief products net sales segment ye ar ende decem b er dollars millions prescription pharmaceuticals animal health consumer health care consolidated net sales profit loss segment yea r ended decem b er dollars millions prescription pharmaceuticals animal health consumer health care corporate including net interest expenseincome million million million respectively consolidated profitloss tax cumulative effect change accounting principle prescription pharmaceuticals segments profit includes charges arising purchase accounting items million animal health segments profit includes charges arising purchase accounting items million prescription pharmaceuticals segments loss includes billion purchase accounting items including acquired inprocess research development billion animal health segments loss includes million purchase accounting items including acquired inprocess research development million scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting see note equity income item financial statements supplementary data additional information equity income merckscheringplough joint venture included prescription pharmaceuticals segment corporate includes interest income expense foreign exchange gains losses currency option gains headquarters expenses special acquisitionrelated charges miscellaneous items table contents accounting policies used segment reporting described note summary significant accounting policies item financial statements supplementary data corporate includes special acquisitionrelated charges million comprised million integration related costs million employee termination costs related productivity transformation program includes ongoing integration obs estimated charges relate reportable segments follows prescription pharmaceuticals million animal health million consumer health million corporate million corporate includes special acquisitionrelated charges million comprised million integration related costs obs acquisition million employee termination costs part integration activities estimated charges relate reportable segments follows prescription pharmaceuticals million animal health million corporate million corporate includes special charges million primarily related changes scheringploughs manufacturing operations us puerto rico announced june related prescription pharmaceuticals segment included cost sales charges approximately million manufacturing streamlining actions primarily related prescription pharmaceuticals segment see note special acquisitionrelated charges manufacturing streamlining item financial statements supplementary data additional information information merckscheringplough joint venture may scheringplough merck entered two separate sets agreements jointly develop manage certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture relies maximum degree possible respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company second quarter joint venture related allergyasthma drug terminated accordance agreements pursuant cholesterol agreements scheringplough granted joint venture limited exclusive license scheringploughs proprietary ezetimibe molecule technology cholesterol agreements provide scheringplough merck develop commercialize ezetimibe cholesterol management field joint venture oncedaily monotherapy marketed zetia us asia ezetrol europe ii coadministration various approved statin drugs iii fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched many international markets scheringplough utilizes equity method accounting recording share activity merckscheringplough joint venture see note equity income item financial statements supplementary data additional information regarding profits costs sharing accounting provided agreements table contents allergyasthma agreements provided joint development marketing companies oncedaily fixedcombination tablet containing loratadinemontelukast april merckscheringplough joint venture received notapprovable letter us food drug administration fda proposed fixed combination loratadinemontelukast second quarter respiratory joint venture terminated accordance agreements action impact cholesterol joint venture result termination respiratory joint venture scheringplough received payments totaling million scheringplough recognized equity income scheringplough merck developing singletablet combination ezetimibe atorvastatin treatment elevated cholesterol levels information centocor licenses remicade prescribed treatment inflammatory diseases rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis remicade scheringploughs second largest marketed pharmaceutical product line cholesterol franchise remicade licensed manufactured centocor inc johnson johnson company scheringplough exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody filed approval europe scheringplough exclusive marketing rights products outside us japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending scheringploughs exclusive rights market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits scheringploughs distribution products scheringplough marketing territory share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products conditioned approval golimumab granted prior september scheringplough may independently develop market golimumab crohns disease indication territories option centocor participate addition scheringplough centocor agreed utilize autoinjector device commercialization golimumab agreed share development costs global operations majority scheringploughs operations outside us acquisition obs late scheringploughs global operations prescription pharmaceuticals animal health increased nonus activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition scheringplough represented markets licensees distribution arrangements currently scheringplough business operations countries additional information global operations see item managements discussion analysis financial condition results operations segment information described k net sales geographic area dollars millions united states europe canada latin america asia pacific consolidated net sales table contents scheringplough subsidiaries countries outside united states net sales presented geographic area scheringploughs customers located following countries accounted percent consolidated net sales past three years consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions total international net sales france japan germany canada net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions mckesson corporation cardinal health supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows p ercentage amount applicable sales dollars millions us nasonex international remicade scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting longlived assets geographic location dollars millions united states netherlands ireland singapore total table contents longlived assets shown geographic location primarily properties significant increase longlived assets due obs acquisition scheringplough disaggregate assets segment basis internal management reporting therefore information presented research development scheringploughs research activities primarily aimed discovering developing new prescription products enhancements existing human prescription products medical commercial significance however scheringploughs research development platform also supports animal health consumer health care products often research development project application one product segment significant work current management team increase productivity efficiency research activities part action agenda produced tangible results scheringplough increased number new molecular entities phase iii three eight yearend four preregistration total latestage development companysponsored research development expenditures billion billion billion respectively percentage consolidated net sales research development expenditures represented approximately percent percent percent respectively scheringploughs research activities concentrated six therapeutic areas focus cardiovascular central nervous system immunology infectious disease oncology respiratory womens health scheringploughs research activities include significant biotechnology immunology vaccine development efforts reflecting portfolio balance small molecule biologic products research activities include expenditures internal research efforts research collaborations various partners number pharmaceutical compounds varying stages development predicted compounds become available commercial sale scheringploughs product pipeline lists significant products development available scheringploughs web site wwwscheringploughcom due nature development approval process well fact human health involved science human health constantly evolving status compounds development subject change scheringplough assume duty update information scheringplough six research development projects granted fasttrack designation fda including novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular events boceprevir protease inhibitor compound hepatitis c vicriviroc ccr receptor antagonist treatment hiv preladenant aa adenosine receptor antagonist treatment parkinsons disease sch next generation protease inhibitor compound hepatitis c iv formulation posaconazole currently approved many countries treatment prophylaxis certain fungal infections products three phase iii clinical testing phase thrombin receptor antagonist boceprevir vicriviroc significant expenditures would required progress development due large number patients necessary phase iii trials scheringplough continues expect research development expenses increase next several years primary reason scheringploughs pipeline larger new management team focused making research development productive additional pipeline projects added obs acquisition reasons include need larger clinical trials frequent clinical trials longer clinical trials current global regulatory environment research development activities typically continue product marketed one reason develop new indications product another reason understand benefit risks may become known people use product longer period time requiring need incremental safety efficacy testing table contents regulatory authorities around world placing increasing emphasis postapproval commitments form new studies registries etc initial approval patents trademarks intellectual property rights overview intellectual property protection critical scheringploughs ability successfully commercialize product innovations schering plough owns applied licensed rights large number patents us countries relating compounds formulations uses manufacturing processes assurance patents scheringplough seeking granted patents scheringplough granted would found valid challenged moreover patents relating particular formulations uses processes preclude manufacturers employing alternative processes marketing alternative formulations uses might successfully compete scheringploughs patented products outside us standard intellectual property protection pharmaceuticals varies widely many countries reasonably strong patent laws countries currently provide little effective protection inventions intellectual property rights traderelated aspects intellectual property agreement trips administered world trade organization wto countries agreed provide nondiscriminatory protection pharmaceutical inventions assure adequate effective rights available patent owners possible changes agreement made future diminish delay implementation developing countries soon assess much scheringplough impacted commercially changes product patent expires patent holder often loses effective market exclusivity product result rapid sharp material decline sales formerly patented product particularly us however cases innovator company obtain additional commercial benefits manufacturing trade secrets laterexpiring patents processes uses formulations trademark use exclusivity may available pharmaceutical regulatory laws scheringploughs intellectual property portfolio patent protection certain scheringplough compounds formulations processes uses important scheringploughs business financial results many scheringploughs products addition patents compound scheringplough holds patents manufacturing processes formulations uses may extend exclusivity beyond expiration compound patent scheringploughs subsidiaries licensed rights number patents patent applications us abroad patents patent applications relating scheringploughs significant products including without limitation vytorin zetia remicade nasonex follistimpuregon nuvaring temodar pegintron clarinex material importance scheringplough worldwide scheringplough sells major products trademarks also material aggregate business financial results trademark protection varies throughout world protection continuing countries long mark used countries long registered registrations normally fixed renewable terms patent challenges hatchwaxman act drug price competition patent term restoration act commonly known hatchwaxman made complex set changes patent new drug approval laws us hatchwaxman drug could approved without providing fda complete safety efficacy studies known complete new drug application nda hatchwaxman authorized fda approve generic versions innovative medicines without information upon filing abbreviated new drug table contents application anda anda generic manufacturer must demonstrate bioequivalence generic version nda approved drug safety efficacy hatchwaxman provides limited patent term restoration partially make patent term lost time ndaapproved drug regulatory review ndaapproved drugs also receive limited period data exclusivity prevents approval anda applications specific time periods approval ndaapproved drug absent successful patent challenge fda approve anda innovators patents listed innovator fda orange book expire however generic manufacturer may file anda seeking approval expiration applicable data exclusivity alleging one patents listed innovators nda invalid infringed allegation commonly known paragraph iv certification innovator must file suit generic manufacturer protect patents one ndalisted patents successfully challenged first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue recent years certain generic companies elected launch generic products risk patent litigation ongoing decision reached court scheringploughs ks qs include listing hatchwaxman act challenges patents legal proceedings section marketing activities competition scheringplough marketing organization trained professional sales representatives introduces makes known prescription drugs health care providers physicians pharmacists hospitals pharmacy benefit managers managed care organizations employers buying groups government agencies scheringplough also introduces makes known prescription products journal advertising direct mail advertising distribution samples physicians scheringplough communicates directly consumers us television radio internet print advertising media scheringplough believes advertising benefit public health increasing awareness diseases educating patients treatment options motivating patients engage dialogue health concerns physicians scheringplough sells prescription drugs wholesale specialty distributors hospitals certain managed care organizations retail specialty pharmacists government agencies scheringplough trained professional sales representatives promotes animal health products veterinarians distributors animal producers scheringplough sells overthecounter otc foot care sun care products wholesale retail drug food chain mass merchandiser outlets scheringplough promotes directly consumer television radio internet print advertising media appropriate scheringplough seeks regulatory approval switch prescription products overthecounter status way otc marketplace another means maximizing return investments discovery development pharmaceutical industry highly competitive includes large companies significantly larger scheringplough substantial resources research product development advertising promotion field selling support competitive pressures intensified pressures environment intensified numerous domestic international competitors industry principal competitive techniques used scheringplough products include research development new innovative improved products varied dosage forms strengths switching prescription products nonprescription status us many scheringploughs products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental thirdparty payers practices us pharmacists table contents pressures toward dispensing generic products may significantly reduce sales certain products competing products therapeutic category longer protected patents exclusivity available pharmaceutical regulatory laws outside us similar competitive pressures additionally europe international markets government regulates pharmaceutical prices access control costs government sponsored healthcare systems possibility us medicare act could amended allow federal government negotiate prices directly manufacturers additionally several states considering price controls access constraints medicaid program government regulation scheringploughs major business segments subject significant regulation multiple jurisdictions section describes general regulatory framework additional information cost regulatory compliance specific impacts scheringploughs business financial condition described heading regulatory competitive environment scheringplough operates managements discussion analysis later k additional information regulatory matters found note legal environmental regulatory matters item financial statements supplementary data prescription pharmaceuticals segment regulations apply phases business including regulatory requirements conduct standards clinical trials example requiring use good clinical practices gcps apply research development stage regulatory requirements conduct standards postapproval clinical trials required regulatory approval begin marketing new drug market existing drug product new indications regulations prescribing manner drugs manufactured packaged labeled advertised marketed distributed regulations impacting pricing drugs regulatory requirements assess report adverse impacts side effects drugs used clinical trials well marketed drugs called pharmacovigilance ability regulatory authorities remove product market modify approved useslabeling recall certain batches products us national regulation phases prescription drug business except pricing centralized fda fda responsible protecting us public health assuring safety efficacy security human veterinary drugs biological products medical devices generally free market pricing us although centers medicare medicaid services cms medicare part b include provisions pricing drugs elderly disabled indigent receive federal prescription benefits scheringplough also committed complying voluntary best practices pharmaceutical research manufacturers america phrma trade industry group member regarding marketing advertising practices eu including scheringploughs key markets united kingdom france germany italy regulation local country level additional regulation eu level european medicines agency emea pharmaceutical products regulated levels various national mutual recognition centralized regulatory procedures emea coordinates evaluation supervision majority medicinal products throughout eu paneu market pricing system however individual member states various systemsagencies regulate price local level japan regulation pharmaceuticals medical device agency pmda pmda regulates pharmaceuticals medical devices development postmarketing use japanese government regulates pricingreimbursement pharmaceutical products japan table contents complicated pricing process includes benchmarks prices western countries us canada select eu countries increasing pressure governmental bodies major markets well thirdparty payors pharmaceutical industry bring products market provide differentiation versus existing products lead expensive scientifically challenging clinical trials order generate type data new products versus marketed comparators us focus product differentiation reliance comparator data accelerated new federal grants provided stimulus package comparative effectiveness reviews billion health information technology billion coupled billion bonus payments medicare medicaid physicians hospitals adopt health information technology improvements difficult predict speed change degree impact new spending regarding pharmaceutical markets branded pharmaceutical products description prescription pricing pressures refer pricing pressures item managements discussion analysis financial condition results operations raw materials raw materials essential scheringploughs operations available adequate quantities number potential suppliers energy expected available scheringplough sufficient quantities meet operating requirements seasonality certain scheringploughs products particularly respiratory sun care products seasonal nature seasonal patterns material effect consolidated operations scheringplough environment date environmental matters material effect scheringploughs operations financial position matters include compliance federal state local laws regarding discharge materials environment protection environment climate change employees december scheringplough approximately employees worldwide approximately employees united states approximately employees outside united states available information scheringploughs ks qs ks amendments reports filed furnished us securities exchange commission sec available free charge scheringploughs web site soon reasonably practicable materials electronically filed sec scheringploughs internet address wwwscheringploughcom since scheringplough began practice third quarter report available scheringploughs web site within hours filing reports filed scheringplough sec may read copied secs public reference room f street ne washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxies information statements information regarding issuers file electronically sec item risk factors scheringploughs future operating results cash flows may differ materially results described k due risks uncertainties related scheringploughs business including discussed table contents addition factors represent risks uncertainties could cause actual results differ materially implied forwardlooking statements contained report key scheringplough products generate significant amount scheringploughs profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows scheringploughs ability generate profits operating cash flow depends largely upon continued profitability schering ploughs cholesterol franchise consisting vytorin zetia key products remicade temodar nasonex pegintron clarinex follistim claritin remeron nuvaring result scheringploughs dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic otc availability scheringploughs product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason high risk funds invested research generate financial returns development novel drugs requires significant expenditures low probability success high rate failure inherent research develop new drugs treat diseases result high risk funds invested scheringplough research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested scheringploughs success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications increasing uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others intellectual property protection innovation important contributor scheringploughs profitability generic forms scheringploughs products may introduced market result expiration patents covering scheringploughs products successful challenge scheringploughs patents atrisk launch generic version scheringplough product may material negative effect results operations intellectual property protection critical scheringploughs ability successfully commercialize products patents relating scheringploughs significant products may material importance scheringplough upon expiration successful challenge scheringploughs patents covering product competitors may introduce lowerpriced generic similar branded versions product may include scheringploughs wellestablished products generic manufacturer may file abbreviated new drug application seeking approval expiration applicable data exclusivity alleging one patents listed table contents innovators new drug application invalid infringed unenforceable allegation commonly known paragraph iv certification innovator ability file suit generic manufacturer enforce patents generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue recent years generic manufacturers launched generic versions products ultimate resolution patent litigation commonly known atrisk product launches generic entry may result loss significant portion sales downward pressures prices scheringplough offers formerly patented products please refer legal proceedings item k descriptions pending intellectual property litigation additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect scheringploughs results operations recent court decisions relating companies us patents potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection patent disputes costly prosecute defend adverse judgments could result damage awards increased royalties similar payments decreased sales patent positions highly uncertain patent disputes pharmaceutical industry unusual adverse result patent dispute involving scheringploughs patents patents collaborators may lead determination court patent infringed invalid andor unenforceable adverse determination could lead scheringploughs loss market exclusivity adverse result patent dispute alleging scheringplough infringed patents held third party may lead determination court patent infringed valid enforceable adverse determination may preclude commercialization schering ploughs products andor may lead significant financial damages past ongoing infringement due uncertainty surrounding patent litigation parties may settle patent disputes obtaining license mutually agreeable terms order decrease risk interruption manufacturing andor marketing products potential litigation regarding scheringploughs intellectual property rights always exists litigation may initiated third parties attempting abridge scheringploughs rights even scheringplough ultimately successful particular dispute scheringplough may incur substantial costs defending patents intellectual property rights see patent challenges hatchwaxman act item legal proceedings list current paragraph iv certifications scheringplough products multijurisdictional regulations including establishing scheringploughs ability price products may negatively affect scheringploughs sales profit margins scheringplough faces increasing pricing pressure globally managed care organizations institutions government agencies programs could negatively affect scheringploughs sales profit margins example us medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulted increased use generics increased purchasing power negotiating behalf medicare recipients turn resulted increased price pressure scheringploughs products addition legislation concerning price controls trends could adversely affect scheringploughs sales profit margins trends include legislative regulatory action relating pharmaceutical pricing reimbursement health care reform initiatives drug importation legislation involuntary approval medicines otc use trends also include nongovernmental initiatives practices consolidation among customers managed care practices health care costs containment increasingly market approval reimbursement products prescribers practices policies thirdparty payors may table contents influenced health technology assessments national institute health clinical excellence uk organizations us result governments efforts reduce health care expenditures payors efforts reduce health care costs scheringplough faces increased pricing pressure payors continue seek price discounts respect scheringploughs products countries many governmental agencies strictly control directly indirectly prices pharmaceutical products sold markets cost control methods including restrictions physician prescription levels patient reimbursements emphasis greater use generic drugs acrosstheboard price cuts may decrease revenues internationally acquisition obs scheringplough acquired marketed products pipeline projects new therapeutic areas including womens health central nervous system carry unique risks uncertainties could negative impact future results operations cash flows acquisition obs scheringplough acquired products additional therapeutic areas therapeutic area presents different risk profile including different benefits safety issues must balanced scheringplough regulators various research development marketing decisions made unique product liability risks different patient prescriber priorities different societal pressures adding new therapeutic areas may strengthen scheringploughs business increasing sales profits making combined company relevant patients prescribers diversifying enterprise risk across areas positives may outweigh additional risk particular therapeutic area could result unanticipated costs could significant adverse impact results operations cash flows market forces continue evolve impact scheringploughs ability sell products price scheringplough charge products number intermediaries involved drug manufacturers scheringplough patients use drugs intermediaries impact patients ability prescribers ability choose pay particular drug may adversely affect sales particular scheringplough drug intermediaries include health care providers hospitals clinics payors representatives employers insurers managed care organizations governments others supply chain pharmacists wholesalers examples include payors require patient first fail one generic less expensive branded drugs reimbursing effective branded product expensive payors increasing patient copayment amounts hospitals stock administer generic product inpatients managed care organizations may penalize doctors prescribe outside approved formularies may include branded products generic available pharmacists receive larger revenues dispense generic drug branded drug intermediaries required routinely provide transparent data patients comparing effectiveness generic branded products disclose economic benefits tied steering patients toward requiring patients use generic products rather branded products government investigations involving scheringplough could lead commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs could give rise investigations litigation government entities private parties scheringplough predict whether future pending investigations may become subject would lead judgment settlement involving significant monetary award restrictions operations pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department table contents justice us attorneys offices office inspector general department health human services fda federal trade commission various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs addition adverse outcome government investigation could prompt government entities commence investigations scheringplough cause entities private parties bring civil claims scheringplough also predict whether investigations affect marketing practices sales result could material adverse impact schering ploughs results operations cash flows financial condition business number governmental entities us made inquiries initiated investigations timing disclosures relating enhance clinical trial include several letters congress investigations state attorneys general offices requests information us attorneys offices department justice regardless merits outcomes investigation government investigations costly divert managements attention scheringploughs business may result substantial damage scheringploughs reputation see item legal proceedings litigation investigations relating merckscheringplough cholesterol joint venture information merckscheringplough cholesterol joint ventures enhance clinical trials related matters legal matters adverse outcomes could negatively affect scheringploughs results operations cash flows financial condition business unfavorable outcomes pending litigation matters future litigation including litigation concerning product pricing securities law violations product liability claims erisa matters patent intellectual property disputes antitrust matters could preclude commercialization products negatively affect profitability existing products subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs result could materially adversely affect scheringploughs results operations cash flows financial condition business aggressive plaintiffs counsel often file litigation wide variety allegations whenever media attention negative discussion efficacy safety product whenever stock price volatile even allegations groundless scheringplough may need expend considerable funds resources respond litigation please refer legal proceedings item k descriptions significant pending litigation issues concerning merckscheringplough cholesterol joint ventures clinical trials could material adverse effect joint ventures sales vytorin zetia turn could material adverse impact scheringploughs financial condition see item legal proceedings litigation investigations relating merckscheringplough cholesterol joint venture information merckscheringplough cholesterol joint ventures enhance clinical trials related matters significant negative media surrounding release enhance results merckscheringplough cholesterol joint ventures enhance seas clinical trial results reviewed vytorin zetia may receive additional media attention connection clinical table contents trials could lead reduced sales affect enrollment clinical trials current future investigations analysis enhance seas clinical trials data various agencies litigation concerning sale promotion products securities class action litigation relating matters could resolved unfavorably scheringplough joint venture material adverse effect scheringploughs results operations cash flow financial position scheringplough third parties acting behalf subject governmental regulations failure comply well costs compliance regulations may adversely affect scheringploughs results operations cash flow financial position manufacturing research practices scheringplough third parties acting behalf must meet stringent regulatory standards subject regular inspections cost regulatory compliance including associated compliance failures materially affect scheringploughs results operations cash flow financial position failure comply regulations include pharmacovigilance reporting requirements standards relating clinical laboratory manufacturing practices result suspension termination clinical studies delays failure obtaining approval drugs seizure recalls drugs suspension revocation authority necessary production sale drugs withdrawal approval fines civil criminal sanctions scheringplough also subject regulations including environmental health safety labor regulations developments following regulatory approval may adversely affect sales scheringploughs products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials may decrease demand scheringploughs products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals companies significant safety issues health authorities fda emea pmda increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications reviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially us advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects scheringploughs products could significantly reduce demand product require scheringplough take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current table contents environment pharmaceutical companies operate scheringplough risk product liability claims products new products technological advances developed scheringploughs competitors may negatively affect sales scheringplough operates highly competitive industry scheringplough competes large number multinational pharmaceutical companies biotechnology companies generic pharmaceutical companies many scheringploughs competitors conducting research development areas served scheringploughs current products products scheringplough process developing competitive developments may impact scheringplough include technological advances patents granted new products developed competitors new existing generic prescription andor otc products compete products scheringplough merckscheringplough cholesterol joint venture addition possible doctors patients providers may favor products offered competitors due safety efficacy pricing reimbursement characteristics result scheringplough unable maintain sales products competition third parties may make difficult scheringplough acquire license new products product candidates regardless stage development enter transactions terms permit scheringplough generate positive financial impact scheringplough depends acquisition inlicensing arrangements source new products opportunities obtaining licensing new products limited however securing rights typically requires substantial amounts funding substantial resource commitments scheringplough competes opportunities many companies third parties greater financial resources greater ability make resource commitments scheringplough may able acquire license new products could adversely impact scheringplough prospects scheringplough may also difficulty acquiring licensing new products acceptable terms secure rights new products scheringplough may make substantial financial resource commitments could limit ability produce positive financial impact transactions scheringplough relies thirdparty relationships key products conduct changing circumstances third parties may adversely impact business scheringplough several relationships third parties scheringplough depends many key products often third parties compete scheringplough interests aligned interests scheringplough notwithstanding contracts scheringplough third parties scheringplough may able control influence conduct parties circumstances affect either could adversely impact scheringplough relationships longstanding third partys work scheringploughs work evolves priorities alignments also change times new issues develop anticipated time contracts negotiated new issues related uncertainties contracts also adversely impact scheringplough scheringploughs global operations expose scheringplough additional risks adverse event could material negative impact results operations majority scheringploughs operations outside us acquisition obs late scheringploughs global operations prescription pharmaceuticals animal health increased acquisitions recently completed purchase obs expanded size scale scope scheringploughs global operations risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets table contents multiple regulatory requirements could restrict scheringploughs ability manufacture sell products key markets trade protection measures import export licensing requirements diminished protection intellectual property countries possible nationalization expropriation addition may changes scheringploughs business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease integration businesses scheringplough obs create combined company complex process may subject unforeseen developments could adverse impact results future operations two companies combined workforces scheringplough obs continue face uncertainties completion integration phase cultural integration particularly transatlantic transactions complex take several years although substantial progress made towards completing integration phase obs acquisition quickly possible difficult predict long integration phase last workforces companies learning use new processes work integrated streamlined employees new combined company past worked usbased global company applicable regulatory requirements different number respects substantial efforts made facilitate smooth execution integration including thorough training transparent motivational employee communications may increased risk slower execution various work processes repeated execution achieve quality standards reputational harm event compliance failure new complex regulatory requirements even failure inadvertent events could adverse impact results future operations acquisition obs expanded scheringploughs animal health business worldwide increases risk negative events animal health industry could negative impact future results operations acquisition obss animal health business scheringploughs global animal health business significant business segment combined companys future sales key animal health products could adversely impacted number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy bse mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact scheringploughs results operations also outbreak highly contagious diseases near scheringploughs main production sites could require scheringplough immediately halt production vaccines sites force scheringplough incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment scheringploughs business becomes significant impact events future results operations would also become significant table contents acquisition obs increased scheringploughs biologics human animal health product offerings including animal health vaccines biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions us european states within eu could result restricted access transport use materials scheringplough loses access sufficient sources materials tighter restrictions imposed use materials scheringplough may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda emea regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example us biologics license application including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval release manufactured lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process scheringplough may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs currently process us submission approval generic biologics based upon abbreviated data packages showing sameness another approved biologic public dialogue fda congress regarding scientific statutory basis upon products known biosimilars followon biologics could approved marketed us scheringplough certain congress create statutory pathway approval biosimilars schering plough predict impact approval biosimilars would sales scheringplough products us europe however emea issued guidelines approving biological products abbreviated pathway biosimilars approved europe biosimilar version one scheringploughs products approved europe could negative effect sales product scheringplough exposed market risk fluctuations currency exchange rates interest rates scheringplough operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally scheringplough entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure table contents since scheringplough certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect scheringploughs results operations financial position cash flows order mitigate adverse impact market fluctuations scheringplough time time enter hedging agreements hedging agreements currency options interest rate swaps limit exposure exchange rate interest rate fluctuations attempts mitigate risks costly always successful current stock market credit market conditions extremely volatile unpredictable difficult predict whether conditions continue worsen whether conditions would impact scheringplough whether impact could material scheringplough exposure many different industries counterparties including commercial banks investment banks suppliers customers include wholesalers managed care organizations governments may unstable may become unstable current economic environment instability may impact parties ability fulfill contractual obligations scheringplough might limit place burdensome conditions upon future transactions scheringplough customers may also reduce spending times economic uncertainty also possible suppliers may negatively impacted events could resulting material adverse impact operations results operations although scheringplough currently plan access equity debt markets meet capital liquidity needs constriction volatility markets may restrict future flexibility unforeseen capital liquidity needs arise current conditions resulted severe downward pressure stock credit markets could reduce return available invested corporate cash reduce return investments held pension plans thereby potentially increase funding obligations severe sustained could material adverse impacts scheringploughs results operations financial position cash flows insurance coverage product liability may limited cost prohibitive unavailable scheringplough maintains insurance coverage deductibles selfinsurance reflect market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly certain products thirdparty insurance increasingly cost prohibitive available limited terms past coverage unavailable schering plough selfinsures substantially risk relates products liability availability commercial insurance become restrictive scheringplough continually assesses best way provide insurance needs scheringplough subject evolving complex tax laws may result additional liabilities may affect results operations scheringplough subject evolving complex tax laws jurisdictions operates significant judgment required determining scheringploughs tax liabilities scheringploughs tax returns periodically examined various tax authorities schering plough believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition scheringplough may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions table contents item b unresolved staff comments none item properties scheringploughs corporate global pharmaceutical headquarters located kenilworth new jersey scheringploughs animal health global headquarters located boxmeer netherlands principal us research facilities located kenilworth union summit new jersey palo alto california nebraska animal health principal research facilities outside us located netherlands scotland principal manufacturing facilities follows location product type belgium pharmaceuticals brazil pharmaceuticals animal health cleveland tennessee usa consumer products france pharmaceuticals ireland pharmaceuticals consumer products animal health kenilworth new jersey usa pharmaceuticals consumer products mexico pharmaceuticals millsboro delaware usa animal health netherlands pharmaceuticals animal health omaha nebraska usa animal health puerto rico pharmaceuticals research triangle park north carolina usa pharmaceuticals singapore pharmaceuticals scheringplough owns majority properties general properties adequately maintained suitable purposes discussed detail part ii k certain scheringploughs manufacturing sites operate capacity april scheringplough announced part productivity transformation program would reduction number plants worldwide goal creating focused highefficiency network plants analysis optimal configuration plants ongoing item legal proceedings material pending legal proceedings ordinary routine litigation incidental business scheringplough corporation subsidiaries property subject disclosed additional information legal proceedings including important financial information found note legal environmental regulatory matters contained item financial statements supplementary data patent matters described patents trademarks intellectual property rights item business k intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect schering plough table contents patent challenges hatchwaxman act scheringplough currently believe pending paragraph iv certification proceeding hatchwaxman act material frequently media investor interest proceedings scheringplough listing pending proceedings quarter currently following pending july scheringplough licensor cancer research technologies limited filed patent infringement action companies seeking approval generic version certain strengths temodar capsules trial scheduled begin march us district court district delaware march scheringplough entity jointly owned merck filed patent infringement action companies seeking approval generic version zetia september dates thereafter scheringplough filed patent infringement actions companies seeking approval generic versions clarinex tablets clarinex reditabs clarinex clarinex scheringplough settled majority companies continues litigate three remaining defendants terms settlements generic versions clarinex reditabs clarinex clarinex launched earlier january generic version clarinex tablet launched earlier july assuming certain conditions met february scheringplough licensor filed patent infringement action company seeking approval generic version integrilin awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege schering plough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks table contents compensatory damages behalf class court certified shareholder class october notice pendency class action sent members class july february court signed order preliminarily approving settlement agreement proposed settlement agreement scheduled presented final approval hearing june erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain former corporate officers breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anti competitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages february special master recommended us district court district new jersey dismiss class action lawsuits summary judgment thirdparty payor actions several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation litigation investigations relating merckscheringplough cholesterol joint venture background january merckscheringplough cholesterol joint venture announced results enhance clinical trial effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia july merckscheringplough cholesterol joint venture announced results seas clinical trial simvastatin ezetimibe aortic stenosis litigation investigations respect matters relating clinical trials disclosed prior filings please refer legal proceedings item scheringploughs ka part ii item legal proceedings forms q periods ending march june september also see part ii information recent cholesterol clinical trials forms q periods ending june september scheringplough cooperating fully various investigations responding requests information scheringplough intends vigorously defend lawsuits filed relating enhance study investigations inquiries date filing k scheringplough joint venture andor joint venture partner merck received number governmental inquiries subject number investigations inquiries relating enhance clinical trial include several table contents letters congress including subcommittee oversight investigations house committee energy commerce ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related merckscheringplough cholesterol joint ventures enhance clinical trial also include several subpoenas state officials including state attorneys general requests information us attorneys department justice seeking similar information documents addition scheringplough received letters subcommittee oversight investigations house committee energy commerce seeking certain information documents related seas clinical trial matters scheringplough merck joint venture cooperating investigations responding inquiries january initial release enhance data fda stated would review results enhance trial january fda announced results review fda stated following two years treatment carotid artery thickness increased mm vytorin group mm simvastatin group difference changes carotid artery thickness two groups statistically significant levels ldl cholesterol decreased vytorin group decreased simvastatin group difference reductions ldl cholesterol two groups statistically significant fda also stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease fda also stated pending results improveit clinical trial patients stop taking vytorin cholesterol lowering medications talk doctors questions litigation scheringplough continues respond existing new litigation including civil class action lawsuits alleging common law state consumer fraud claims connection scheringploughs sale promotion merckscheringplough joint venture products vytorin zetia several putative shareholder securities class action lawsuits several officers also named defendants alleging false misleading statements omissions scheringplough representatives related timing disclosures concerning enhance results allegedly violation sections b securities exchange act putative shareholder securities class action lawsuit several officers directors also named alleging material misstatements omissions related enhance results offering documents connection scheringploughs securities offerings allegedly violation securities act including section several putative class action suits alleging scheringplough certain officers directors breached fiduciary duties erisa seeking damages amount losses allegedly suffered plans shareholder derivative action alleging board directors breached fiduciary obligations relating timing release enhance results letter behalf single shareholder requesting board directors investigate allegations litigation described warranted bring appropriate legal action behalf scheringplough tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation tried newark district court decision yet rendered scheringploughs tax reserves adequate cover abovementioned payments table contents pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection settlement massachusetts investigation commencing new fiveyear term failure comply obligations cia could result financial penalties date scheringplough believes complied obligations matters products liability beginning may number complaints filed various jurisdictions asserting claims organon usa inc organon pharmaceuticals usa inc organon international organon scheringplough corporation arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation venued missouri new jersey state court cases pending states french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court april competitor also requested interim relief portion granted french competition authority december interim relief required scheringploughs french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority january french supreme court confirmed decision french competition authority item submission matters vote security holders applicable executive officers registrant listed executive officers corporate officers scheringplough february unless otherwise indicated held position indicated past five years officers serve one year successors duly appointed table contents name title ge robert j bertolini executive vice president chief financial officer john carroll vice president global internal audits c ron cheeley senior vice president global human resources carrie cox executive vice president president global pharmaceuticals william j creelman vice president tax fred hassan chairman chief executive officer maria teresa hilado vice president treasurer steven h koehler vice president controller thomas p koestler phd executive vice president president scheringplough research institute raul e kohan senior vice president president intervetscheringplough animal health ian mcinnes phd senior vice president president global supply chain lori queisser senior vice president global compliance business practices thomas j sabatino jr executive vice president general counsel karl salnoske vice president chief information officer brent saunders senior vice president president consumer health care susan ellen wolf corporate secretary associate general counsel vice president governance officers defined rule af securities exchange act mr bertolini joined scheringplough executive vice president chief financial officer mr bertolini partner pricewaterhousecoopers mr carroll joined scheringplough vice president global internal audits mr carroll vice president general auditor american standard companies general auditor american standard companies mr cheeley joined scheringplough senior vice president global human resources mr cheeley group vice president global compensation benefits pharmacia corporation ms cox joined scheringplough executive vice president president global pharmaceuticals ms cox executive vice president president global prescription business pharmacia corporation mr creelman joined scheringplough vice president tax mr creelman senior tax counsel pfizer mr creelman assistant vice president international tax cigna corporation mr hassan joined scheringplough chairman board chief executive officer mr hassan chairman board chief executive officer pharmacia corporation ms hilado joined scheringplough may vice president treasurer ms hilado assistant treasurer general motors corporation january april chief financial officer gmac commercial finance mr koehler joined scheringplough vice president controller mr koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicines company table contents dr koestler named executive vice president president scheringplough research institute september dr koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affairs pharmacia corporation mr kohan named senior vice president president intervetscheringplough animal health october mr kohan deputy head animal health senior vice president corporate excellence administrative services scheringplough corporation end october mr kohan senior vice president president animal health february october group head global specialty operations president animal health dr mcinnes named senior vice president president global supply chain february dr mcinnes joined scheringplough senior vice president global supply chain dr mcinnes senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc ms queisser joined scheringplough february senior vice president global compliance business practices ms queisser vice president chief compliance officer eli lilly company october february mr sabatino joined scheringplough executive vice president general counsel mr sabatino senior vice president general counsel baxter international inc mr salnoske joined scheringplough vice president chief information officer mr salnoske ceo adaptive trade mr saunders joined scheringplough senior vice president global compliance business practices mr saunders partner pricewaterhousecoopers prior joining scheringplough ms wolf named vice president corporate secretary associate general counsel held various positions schering ploughs law department part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market scheringploughs common stock new york stock exchange additional information required item incorporated reference table captioned quarterly data unaudited item financial statements supplementary data following table provides information respect purchases scheringplough common shares fourth quarter issuer purchases equity securities total number aximum number shares purchased shares may average part publicly yet purchased total number price paid announced plans plans period shares purchased per share programs programs october october na na november november na na december december na na total october december na na table contents shares included table represent shares delivered scheringplough option holders payment exercise price tax withholding obligations connection stock options stock awards pursuant scheringploughs stock incentive program performance graph comparison cumulative total return scheringplough corporation composite peer group sp index graph assumes investment december reinvestment dividends scheringploughs common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck pfizer inc wyeth table contents item selected financial data millions except per share figures percentages operating results net sales equity income incomeloss income taxes cumulative effect change accounting principle net incomeloss net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share research development expenses acquired inprocess research development depreciation amortization expenses financial position cash flows property net total assets longterm debt shareholders equity capital expenditures financial statistics net incomeloss percent net sales return average shareholders equity net book value per common share data cash dividends per common share cash dividends paid common shares cash dividends paid preferred shares average shares outstanding used calculating diluted earningsloss per common share average shares outstanding used calculating basic earningsloss per common share common shares outstanding yearend operating results financial information reflects operations obs business subsequent acquisition november including impacts purchase accounting accordance sfas business combinations include special acquisitionrelated charges manufacturing streamlining costs respectively see note special acquisitionrelated charges manufacturing streamlining additional information charges incurred special charges incurred million included litigation charges million employee termination costs million asset impairment charges million special charges incurred included million employee termination costs million asset impairment related charges increase longterm debt compared primarily reflects financing obs acquisition table contents assumes conversion mandatory convertible preferred stock approximately million common shares assumes conversion mandatory convertible preferred stock approximately million common shares million common shares million common shares mandatory convertible preferred stock converted common shares item managements discussion analysis financial condition results operations executive summary overview scheringplough scheringplough innovationdriven sciencecentered global health care company scheringplough discovers develops manufactures pharmaceuticals three customer markets prescription animal health consumer research development activity directed toward prescription products important applications central research development platform animal health products consumer health care products scheringplough also accesses external innovation via partnering inlicensing acquisition three customer markets strategy focused science soon fred hassan elected chairman board chief executive officer scheringplough corporation initiated sixtoeight year strategic plan called action agenda key component action agenda applying science meet unmet medical needs core strategy scheringplough invest substantial funds scientific research goal creating therapies treatments address important unmet medical needs also commercial value consistent core strategy scheringplough increased investment research development scheringplough successful advancing pipeline several late stage projects require sizable resources complete scheringplough continues develop laterphase pipeline compounds eg golimumab sugammadex us thrombin receptor antagonist vicriviroc boceprevir asenapine progressing early pipeline includes drug candidates across wide range therapeutic areas another key component action agenda focus building longterm value shareholders patients rely upon scheringploughs drugs longerterm focus includes concurrent emphasis growing sales disciplined cost controls investing research development future early hassan new management team recruited applied action agenda stabilizing repairing turning around scheringplough scheringplough encountered challenges earlier decade prior management team currently scheringplough continues work fourth five phases action agenda fourth build base phase scheringplough continues focus strategy value creation across broad front past five years sales scheringplough pharmaceutical products across array therapeutic areas showed strong growth compared prior periods pharmaceutical companies scheringploughs pharmaceutical sales marketing activities expanded newer markets geographic diversity adds growth makes performance less sensitive one geographic area substantial progress made integration organon biosciences nv obs purchased akzo nobel late acquisition transformative giving scheringplough key new pipeline projects including asenapine schizophrenia bipolar disease sugammadex reverse deep anesthesia key products two new therapeutic areas womens health central nervous system position leader animal health combining scheringplough animal health intervet leadership position animal vaccines intervet earlystage innovation capabilities human vaccines nobilon table contents additional stateoftheart biologics capabilities substantial expansion companys geographic footprint significant talent including key research development functions april scheringplough announced productivity transformation program ptp goal program includes ongoing integration obs create leaner stronger company support scheringploughs goal building longterm high performance despite current challenging pharmaceutical industry environment particular challenges facing scheringplough program targets savings billion annualized basis designed reduce avoid costs increasing productivity total targeted savings approximately billion anticipated accomplished end balance achieved targeted savings envisioned program include resulting previously announced obs integration synergies beyond program scheringplough anticipates investing new highpriority clinical trials pursuit strategic opportunities including product launches anticipates natural cost growth part action agenda scheringplough continues work enhance infrastructure upgrade processes systems strengthen talent efforts implemented companywide basis scheringplough focusing especially research development support scheringploughs sciencebased business pharmaceutical industry increasing political regulatory pressure particularly united states scheringplough merckscheringplough cholesterol joint venture encountered specific challenges explained detail item legal proceedings litigation investigations relating merckscheringplough cholesterol joint venture strength scheringplough built earlier phases action agenda including diversified group products customer segments geographic areas well highly experienced executive team helpful weathering current future challenges including relating merckscheringplough cholesterol joint venture results highlights scheringploughs performance follows scheringploughs net sales billion increase billion percent compared increase net sales primarily due contribution products obs net sales outside us totaled billion approximated percent consolidated net sales net income available common shareholders billion includes gain divestitures certain animal health products increased sales pharmaceutical products remicade temodar nasonex well increased sales animal health segment contributed favorably scheringploughs overall operating results overall operating results also benefited increased sales obs products global combined net sales scheringploughs cholesterol franchise products vytorin zetia decreased percent compared combined net sales products vytorin zetia us decreased percent compared strategic alliances typical pharmaceutical industry scheringplough licenses manufacturing marketing andor distribution rights certain products others also manufactures markets andor distributes products owned others pursuant licensing joint venture arrangements time third parties involved additional factors relating third party outside control scheringplough may table contents create positive negative impacts scheringplough vytorin zetia remicade subject arrangements key scheringploughs current business financial performance addition potential strategic alternatives may impacted change control provisions arrangements could result vytorin zetia acquired merck remicade golimumab reverting back centocor change control provision relating vytorin zetia included contract merck filed exhibit r k change control provision relating remicade golimumab contained contract centocor filed exhibit v k cholesterol franchise scheringploughs cholesterol franchise products vytorin zetia managed joint venture scheringplough merck treatment elevated cholesterol levels markets outside japan zetia scheringploughs novel cholesterol absorption inhibitor vytorin combination zetia zocor simvastatin statin medication developed merck financial commitment compete cholesterolreduction market shared merck profits sales vytorin zetia also shared merck operating results joint venture merck recorded using equity method accounting cholesterolreduction market single largest pharmaceutical category world vytorin zetia competing market global total combined sales vytorin zetia decreased percent compared total combined sales vytorin zetia us declined percent compared total combined sales vytorin zetia outside us increased percent compared december total combined prescription share vytorin zetia us versus december percent percent past scheringploughs profitability largely dependent upon performance cholesterol franchise performance cholesterol franchise still material scheringplough product diversity become stronger obs acquisition well development scheringplough products dependence cholesterol franchise lessening japan included joint venture merck japanese market bayer healthcare comarketing scheringploughs cholesterolabsorption inhibitor zetia approved japan april monotherapy coadministered statin use patients hypercholesterolemia familial hypercholesterolemia homozygous sitosterolemia zetia launched japan june scheringploughs sales zetia japan comarketing agreement bayer healthcare recognized net sales included pharmaceuticals license arrangements centocor remicade prescribed treatment inflammatory diseases rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis remicade scheringploughs secondlargest marketed pharmaceutical product line cholesterol franchise remicade licensed manufactured centocor inc johnson johnson company scheringplough exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody filed approval europe scheringplough exclusive marketing rights products outside us japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending scheringploughs rights exclusively market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits schering ploughs distribution products scheringplough marketing territory share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products table contents conditioned approval golimumab granted prior september scheringplough may independently develop market golimumab crohns disease indication territories option centocor participate addition scheringplough centocor agreed utilize autoinjector device commercialization golimumab agreed share development costs manufacturing sales marketing scheringplough supports commercialized products manufacturing sales marketing efforts scheringplough also moving forward additional investments enhance infrastructure business including capital expenditures drug development process products moved drug discovery pipeline markets information technology systems postmarketing studies monitoring scheringplough continually reviews business including manufacturing operations identify actions enhance longterm competitiveness however scheringploughs manufacturing cost base relatively fixed actions significantly reduce scheringploughs manufacturing infrastructure including specific reductions number scheringplough manufacturing facilities made part productivity transformation program involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements future events decisions may lead asset impairments related costs regulatory competitive environment scheringplough subject jurisdiction various national state local regulatory agencies regulatory compliance complex costly impacting timing needed bring new drugs market market drugs new indications scheringplough engages clinical trial research many countries around world research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eu member states clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products number intermediaries involved drug manufacturers scheringplough patients use drugs intermediaries impact patients ability prescribers ability choose pay particular drug intermediaries include health care providers hospitals clinics payors representatives employers insurers managed care organizations governments others supply chain pharmacists wholesalers us many scheringploughs pharmaceutical products subject increasingly competitive pricing certain intermediaries including managed care groups institutions government agencies seek price discounts international markets scheringplough operates environment governmentmandated costcontainment programs also pricing sales marketing programs arrangements related business practices scheringplough participants health care industry continued scrutiny federal state regulatory investigative prosecutorial administrative entities market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors loss patent protection due challenges competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature obs acquisition november scheringplough acquired obs purchase price approximately euro billion cash approximately billion table contents commencing acquisition date obss assets acquired liabilities assumed well results obss operations included scheringploughs consolidated financial statements approximately one onehalf months results operations relating obs included scheringploughs statement consolidated operations year ended december impact purchase accounting resulted following noncash charges acquired inprocess research development iprd onetime charge approximately billion amortization inventory adjusted fair value approximately billion charged cost sales million million amortization acquired intangible assets adjusted fair value billion amortized weighted average life years cost sales million million incremental depreciation relating adjustment fair value property plant equipment approximately million depreciated primarily cost sales lives applicable property million million discussion operating results results operations discussed include obss product sales expenses well certain noncash charges relating purchase accounting associated obs acquisition net sales consolidated net sales billion increase billion percent compared consolidated net sales included billion net sales products obs increase primarily due acquisition obs november foreign exchange estimated favorable impact sales since acquisition obs greater proportion schering ploughs sales denominated euros net sales outside us approximately percent consolidated net sales consolidated net sales billion increase billion percent compared consolidated net sales included million net sales products obs related period subsequent acquisition increase primarily reflected growth sales volumes remicade temodar nasonex avelox well contributions animal health consumer health care estimated favorable impact percent foreign exchange significant portion us net sales made major pharmaceutical health care product distributors major retail chains consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler retail trade buying decisions changes overall demand factors factors addition fluctuations sales many pharmaceutical products us subject increased pricing pressure managed care groups institutions government agencies groups seeking discounts scheringplough pharmaceutical manufacturers us market also required provide statutorily defined rebates various government agencies order participate medicaid program veterans health care program governmentfunded programs medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulting increased use generics increased purchasing power negotiating behalf medicare recipients international markets scheringplough operates environment governments may mandated costcontainment programs placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs table contents net sales years ended december follows incre ase dec rease dollars millions prescription pharmaceuticals remicade nasonex temodar pegintron clarinexaerius follistimpuregon nm nm nuvaring nm nm claritin rx avelox integrilin caelyx rebetol zemuron nm nm remeron nm nm intron subutexsuboxone asmanex pharmaceutical nm animal health consumer health care otc foot care sun care consolidated net sales products acquired obs acquisition november nm meaningful percentage sales prescription pharmaceuticals totaled billion billion percent increase compared included billion million net sales related organon human health business obs sales prescription pharmaceuticals totaled billion billion percent increase compared international net sales remicade drug treatment immunemediated inflammatory disorders rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis percent billion compared driven continued market growth expanded penetration certain indications favorable impact foreign exchange international net sales increased percent billion compared due greater demand expanded use across indications favorable impact foreign exchange remicade antitnf antibody marketed schering plough outside us japan certain asian markets competitive products indications referred introduced table contents global net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies rose percent billion compared due increased sales international market percent billion compared product captured greater us international market share competitive products introduced global net sales temodar treatment certain types brain tumors increased percent billion compared due increased sales across geographic regions global net sales increased percent million compared due increased sales across geographic markets including japan product launched september temodar lose patent exclusivity eu global net sales pegintron powder injection pegylated interferon product treating hepatitis c essentially flat compared including favorable impact foreign exchange global net sales increased percent million compared due higher sales latin america emerging markets across europe tempered lower sales japan due increased competition decrease us market size global net sales clarinex marketed aerius many countries outside us treatment seasonal outdoor allergies yearround indoor allergies decreased percent million compared primarily due lower sales united states global net sales increased percent million compared primarily due higher sales international markets global net sales follistimpuregon recombinant folliclestimulating hormone treating infertility million million represent sales date obs acquisition november december follistimpuregon lose patent exclusivity eu global net sales nuvaring contraception product million million represent sales date obs acquisition november december international net sales prescription claritin increased percent million compared primarily due higher sales japan favorable foreign exchange sales increased percent million compared reflecting growth latin america asia pacific japan net sales avelox fluoroquinolone antibiotic treatment certain respiratory skin infections marketed us scheringplough result license agreement bayer decreased percent million compared reflecting decline us respiratory tract infection market net sales increased percent million compared million primarily result increased market share global net sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndrome sold primarily us scheringplough decreased percent million compared sales increased percent million compared international net sales caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increased percent million compared primarily due higher sales across europe favorable foreign exchange sales increased percent million compared primarily due increased sales latin america favorable impact foreign exchange global net sales rebetol capsules use combination pegintron intron treating hepatitis c decreased percent million compared due lower sales japan continued generic competition global net sales decreased percent million compared due lower patient enrollment japan increased generic competition table contents global net sales zemuron muscle relaxant used surgical procedures million million represent sales date obs acquisition november december zemuron lost patent exclusivity us october lose patent exclusivity eu global net sales remeron antidepressant million million represent sales date obs acquisition november december global net sales intron injection chronic hepatitis b c antiviral anticancer indications essentially flat compared decreased percent million compared decrease compared due conversion pegintron treating hepatitis c japan international net sales subutexsuboxone treatment opiate addiction increased percent million compared sales increased percent million compared increases resulted primarily benefit foreign exchange global net sales asmanex orally inhaled steroid asthma percent million compared primarily due market share growth us sales increased million compared due increase sales us pharmaceutical net sales include large number lower sales volume prescription pharmaceutical products included billion million net sales obs products respectively several products sold limited markets outside us many multiplesource products longer protected patents products include treatments respiratory cardiovascular dermatological infectious oncological diseases global net sales animal health products increased percent approximately billion compared included global animal health net sales billion related intervet animal health business obs global net sales benefited solid growth geographic areas led cattle poultry companion animal product lines coupled positive impact foreign currency exchange rates global net sales increased percent billion compared reflecting strong growth core brands across geographic species areas led higher sales companion animal products inclusion intervet sales animal health segments sales impacted intense competition frequent introduction generic products global net sales consumer health care products include otc foot care sun care products increased percent million compared increase mainly due higher sales miralax launched february first rxtootc switch laxative category years offset lower sales otc products otc claritin sales decreased percent million compared result increased competition privatelabel products global net sales increased percent million compared reflecting increase sales sun care products dr scholls products launch miralax addition sales otc claritin increased percent million compared due sales growth across product forms net sales sun care products increased million percent compared primarily due success coppertone continuous spray products launched consumer health care market highly competitive heavy advertising consumers frequent competitive product introductions including former prescription antihistamine launched otc sales early impact us consumers purchasing patterns table contents costs expenses equity income summary costs expenses equity income years ended december follows incre ase dec rease dollars millions gross margin selling general administrative sga research development rd acquired inprocess research development iprd nm nm expenseincome net nm nm special acquisitionrelated charges nm nm equity income nm meaningful percentage substantially sales cholesterol products included scheringploughs net sales results sales reflected equity income addition due virtual nature joint venture scheringplough incurs substantial selling general administrative expenses captured equity income included scheringploughs statements consolidated operations result scheringploughs gross margin ratios sga expenses rd expenses percentage net sales reflect benefit impact joint ventures operating results gross margin gross margin percent compared percent gross margin unfavorably impacted billion million respectively purchase accounting adjustments included cost sales purchase accounting adjustments result amortization fair values primarily inventories intangible assets acquired part obs acquisition gross margin compared benefited realized cost savings approximately million manufacturing streamlining nonrecurrence million charges associated aforementioned manufacturing streamlining actions favorable product mix selling general administrative selling general administrative expenses sga increased percent billion compared increase sga primarily due inclusion expenses obs impact foreign exchange partially offset productivity transformation program savings sga increased percent billion compared reflecting higher promotion spending ongoing investments emerging markets unfavorable impact foreign exchange research development research development rd spending increased percent billion compared included rd upfront payments million mainly related certain licensing transactions increase rd spending versus also reflects increased spending result obs acquisition well higher spending clinical trials related activities investments build greater breadth capacity support scheringploughs expanding global rd pipeline rd spending increased percent billion compared increase due higher costs associated clinical trials well building greater breadth capacity support scheringploughs pipeline changes rd spending also reflect timing scheringploughs funding internal table contents research efforts research collaborations various partners discover develop steady flow innovative products maximize chances successful development new products scheringplough began development excellence initiative build talent critical mass create uniform level excellence deliver highpriority programs within rd schering plough began global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory processes beginning certain aspects global clinical harmonization program implemented continue integrated processes obs expenseincome net expenseincome net comprised following years ended december dollars millions interest cost incurred less amount capitalized construction interest expense interest income foreign exchange lossesgains net gain sale divested products realized gain foreign currency options net ineffective portion interest rate swaps net total expenseincome net scheringplough million expense net million income net interest expense higher due issuance new debt connection acquisition obs second half expense net includes million million tax gain sale divestitures certain animal health products required regulatory agencies us europe connection acquisition obs addition scheringplough recognized gain million million tax sale manufacturing site income net included net realized gains foreign currency options million related obs acquisition increase income net compared also reflected higher interest income due higher balances cash equivalents shortterm investments partially offset higher interest expense due issuance new debt special acquisitionrelated charges manufacturing streamlining special acquisitionrelated charges special acquisitionrelated charges relate productivity transformation program activities include ongoing integration obs business special acquisitionrelated charges million costs included million employee termination costs remaining charges million related integration activities table contents following table summarizes charges cash payments liabilities related productivity transformation program includes ongoing integration obs december acqu ition related liabilities employee employee termination termination exit costs costs costs dollars millions accrued liability december chargesa purchase price allocation itemsb cash payments accrued liability december recorded special acquisitionrelated charges b recorded part purchase accounting included acquisitionrelated liabilities december costs exit certain activities obs special acquisitionrelated charges year ended december scheringplough incurred million special acquisitionrelated charges comprised million integrationrelated costs obs acquisition million employee termination costs part integration activities manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamlined global supply chain enhanced scheringploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new jersey special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico table contents following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed c harges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december severance accrued liability december equity income sales merckscheringplough cholesterol joint venture totaled billion billion billion respectively sales decrease due primarily lower market share us partially offset continued growth international markets sales growth compared due primarily increase market share companies bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement company physician details set annual basis italy contractual amount included profit sharing calculation reimbursed us canada puerto rico amount equal companys agreed physician details multiplied contractual fixed fee scheringplough reports amounts part equity income amounts represent reimbursement specific incremental identifiable costs scheringploughs detailing cholesterol products markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher us market scheringplough receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough generally share profits equally costs joint venture companies contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally scheringplough merck allergyasthma agreements provided joint development marketing companies oncedaily fixedcombination tablet containing loratadinemontelukast april merckscheringplough joint venture received notapprovable letter fda proposed fixed combination loratadinemontelukast second quarter respiratory joint venture terminated accordance agreements action impact cholesterol joint venture result table contents termination respiratory joint venture scheringplough received payments totaling million scheringplough recognized equity income equity income merckscheringplough joint venture totaled billion billion billion respectively decrease equity income amounts compared reflects sales declines vytorin zetia us partially offset sales growth internationally receipt million termination respiratory joint venture increase equity income compared reflected increased sales vytorin zetia compared noted scheringplough incurs substantial selling general administrative costs reflected equity income instead included overall cost structure scheringplough provision income taxes tax expense million million million respectively tax provision amounts included tax benefits million million respectively related amortization fair values certain assets acquired part obs acquisition purchaseaccounting related items tax provisions include benefit related us operating losses scheringplough established valuation allowance net us deferred tax assets including benefit us operating losses management concluded likely benefit us net deferred tax assets realized december scheringplough continues maintain valuation allowance us net deferred tax assets scheringplough expects report us net operating loss nol carryforward billion tax return year ended december us nol carryforward could materially reduced examination scheringploughs income tax returns internal revenue service irs scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax matters litigation see note legal environmental regulatory matters item financial statements supplementary data december total amount unrecognized tax benefits million million respectively includes tax liabilities well reductions deferred tax assets carrying full valuation allowance december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease next twelvemonth period approximately million would primarily attributable decision tax matter currently litigated newark district court decision yet rendered possible final resolution scheringploughs examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment receipt related cash dependent number factors many outside scheringploughs control scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations total amount interest expense related uncertain tax positions years ended december million million respectively total amount accrued interest related uncertain tax positions december million million respectively included accrued liabilities table contents second quarter irs completed examination scheringploughs federal income tax returns schering plough seeking resolution issue raised examination irs administrative appeals process july schering plough made payment million irs pertaining examination scheringploughs tax returns open examination irs tax years irs commenced examination federal income tax returns examination expected completed significant tax jurisdictions us state foreign schering ploughs income tax returns open examination period net incomeloss available common shareholders scheringplough net incomeloss available common shareholders billion billion billion respectively net incomeloss available common shareholders included approximately billion billion respectively charges related purchase accounting obs acquisition net incomeloss available common shareholders included deduction preferred stock dividends million million million respectively related mandatory convertible preferred shares loss due impact purchase accounting items obs acquisition increased interest expense result issuance debt second half amounts partially offset impacts gain currency options period gain divestitures certain animal health products period net incomeloss available common shareholders also included special acquisitionrelated charges manufacturing streamlining costs approximately million million million respectively see note special acquisition related charges manufacturing streamlining item financial statements supplementary data additional information liquidity financial resources discussion cash flow f years en ed december dollars millions cash flow provided operating activities cash flow used investing activities cash flow used forprovided financing activities operating activities operating activities provided billion cash compared net cash provided operations billion increase primarily due inclusion obs business absence special acquisitionrelated payments associated settlement investigation us attorneys office district massachusetts involving certain scheringploughs sales marketing clinical trial practices programs massachusetts investigation net cash provided operating activities billion increase billion compared increase primarily due net realized gain million foreign currency options relating obs acquisition higher net sales equity income partially offset payments million settlement massachusetts investigation million tax interest due connection examination irs scheringploughs federal income tax returns part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options derivatives aggregate premiums approximately million received proceeds table contents million upon termination options resulting net realized gain million derivatives shortterm trading nature hedge specific financing investment transaction accordingly cash impacts derivatives classified operating cash flows statement consolidated cash flows investing activities net cash used investing activities million primarily relates capital expenditures million partially offset proceeds divested products million net cash used investing activities billion primarily consisting billion net cash used purchase obs addition source cash investing activities included net reduction shortterm investments billion partially offset million capital expenditures net cash used investing activities billion primarily related net purchases shortterm investments billion previously invested cash equivalents million capital expenditures financing activities net cash used financing activities billion compared billion cash provided financing activities uses cash financing activities included pay eurodenominated longterm debt euro million debt payments total payments million payment dividends common preferred shares million pay commercial paper shortterm debt outstanding million net cash provided financing activities included net proceeds issuance common preferred shares approximately billion billion respectively net proceeds approximately billion issuance longterm debt net cash provided financing activities also included million proceeds stock option exercises offset payment dividends common preferred shares million net cash used financing activities billion included payment dividends common preferred shares million repayment billion bank debt shortterm commercial paper borrowings discussion cash flows scheringplough expects contribute approximately million retirement plans including approximately million us scheringplough retirement plan december scheringplough net debt total debt less cash cash equivalents shortterm investments marketable securities billion billion respectively cash generated operations available cash shortterm investments available credit facilities expected provide scheringplough ability fund cash needs intermediate term borrowings credit facilities september scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering approximately billion interest notes payable semiannually effective interest rate percent senior unsecured notes percent senior unsecured notes incorporates initial discount debt issuance fees percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values table contents remaining scheduled payments principal interest discounted redemption date semiannual basis using rate treasury notes comparable remaining terms plus basis points notes basis points notes change control triggering event occurs certain circumstances defined prospectus holders notes right require schering plough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase october scheringplough issued euro million aggregate principal amount percent senior unsecured euro denominated notes due euro billion aggregate principal amount percent senior unsecured eurodenominated notes due net proceeds offering approximately billion interest notes payable annually effective interest rate percent senior unsecured eurodenominated notes percent senior unsecured eurodenominated notes incorporates initial discount debt issuance fees impact interest rate hedges percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price specified prospectus change control triggering event occurs certain circumstances defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase scheringplough used net proceeds notes fund portion purchase price obs acquisition october scheringplough entered fiveyear senior unsecured eurodenominated term loan facility syndicate banks october scheringplough drew euro billion billion term loan fund portion purchase price obs acquisition term loan floating interest rate requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing term loan term loan also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets february outstanding balance eurodenominated term loan euro million reported us dollar amounts outstanding debt balance interest expense eurodenominated notes euro denominated term loan fluctuate due impact foreign currency translation november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due interest rates payable notes subject adjustment connection ratings downgrades december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply notes subsequently rated baa moodys bbb sp rating assigned notes either moodys sp downgraded respectively interest rate payable series notes would increase see note borrowings commitments item financial statements supplementary data additional information august scheringplough entered billion revolving credit agreement syndicate banks terminated billion credit facility due mature may credit facility floating interest rate matures august requires scheringplough maintain table contents net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing credit facility credit facility also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets credit line available general corporate purposes considered primarily support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december borrowings outstanding facility december shortterm borrowings including credit facilities mentioned totaled million million respectively outstanding commercial paper december weightedaverage interest rate shortterm borrowings december percent percent respectively scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency translation sfas foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income credit ratings scheringploughs current unsecured senior credit ratings outlook follows longterm senior unsecured credit ratings longterm shortterm review status moodys investors service baa p stable standard poors stable fitch ratings bbb f stable february moodys investors service changed long term review status scheringploughs credit ratings negative outlook stable august standard poors fitch ratings changed long term review status negative watch stable april moodys investor service changed long term review status stable negative outlook fitch ratings changed long term review status stable negative watch march standard poors changed long term review status stable negative watch scheringplough paid entire commercial paper borrowings million cash perspective scheringplough remains invested highlyliquid highlyrated securities scheringplough remains focused credit markets continues closely monitor broader financial economic situation scheringplough believes ability commercial paper issuers schering plough one shortterm credit ratings p moodys sp andor f fitch issue rollover outstanding commercial paper times less companies higher shortterm credit ratings total amount commercial paper capacity available issuers scheringplough typically less higherrated companies addition schering ploughs ability issue commercial paper future dependent capital market conditions time scheringploughs sizable lines credit commercial banks well cash shortterm investments held us international subsidiaries serve alternative sources liquidity scheringploughs credit ratings could decline current levels impact decline could reduce availability commercial paper borrowing would increase interest rate portion scheringploughs short longterm debt discussed scheringplough believes existing table contents cash shortterm investments available credit facilities cash generated operations allow scheringplough fund cash needs intermediate term mandatory convertible preferred stock august scheringplough issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale preferred stock fund portion purchase price obs acquisition share preferred stock automatically convert common shares scheringplough depending average closing price scheringploughs common shares trading day period ending third trading day prior mandatory conversion date august defined prospectus preferred shareholders may elect convert time prior august minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price scheringploughs common shares exceeds least trading days within period consecutive trading days scheringplough may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares share preferred stock preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent scheringplough legally permitted pay dividends board directors declares dividend payable scheringplough pay dividends dividend payment date dividend payment dates february may august november year year ended december shares percent mandatory convertible preferred stock issued august preferred stock converted shares scheringplough common stock equity issuance treasury shares august scheringplough issued common shares treasury shares per share net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale common shares fund portion purchase price obs acquisition see note acquisition item financial statements supplementary data contractual obligations offbalance sheet arrangements scheringplough various contractual obligations reported liabilities consolidated balance sheets others required recognized liabilities certain purchase table contents commitments executory contracts following table summarizes payments due period scheringploughs known contractual obligations december p ayme nts due b perio total thereafter dollars millions shortterm borrowings current portion longterm debt longterm debt obligations interest related debt obligations operating lease obligations purchase obligations deferred compensation plan obligations obligations total purchase obligations include advertising research contracts capital expenditure commitments inventory expense items potential milestone payments approximately billion included contractual obligations table contingent achievement various research development approximately million regulatory approval approximately million salesbased approximately billion milestones research development regulatory milestones depend upon future clinical developments well regulatory agency actions may never occur salesbased milestones contingent generating levels sales current future products yet achieved caption includes obligations based undiscounted amounts estimated payments certain scheringploughs pension plans preferred stock dividends managements estimate current portion unrecognized tax benefits contractual obligations regulatory competitive environment scheringplough operates scheringplough subject jurisdiction various national state local regulatory agencies regulations schering plough subject described detail part item business k regulatory compliance complex regulatory standards including good clinical practices good laboratory practices good manufacturing practices vary jurisdiction constantly evolving regulatory compliance also costly regulatory compliance also impacts timing needed bring new drugs market market drugs new indications failure comply regulations result delays approval drugs seizure recall drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions regulatory compliance cost compliance failures material impact scheringploughs results operations cash flows financial condition much still unknown science human health every drug benefits risks societal governmental pressures constantly shifting demand innovation meet urgent unmet medical needs adversity risk pressures impact regulatory environment market scheringploughs products regulatory compliance pharmacovigilance regulatory inspections scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eu member states requirements differ jurisdiction table contents jurisdiction include requirements reporting adverse events occur patient using particular drug order alert drugs manufacturer governmental agency potential problems february scheringplough began global clinical harmonization program building clinical excellence trial design execution tracking strengthening scheringploughs scientific compliance rigor global basis certain aspects global clinical harmonization program implemented significant work continued expected continue several years scheringplough intends continue upgrading skills processes systems clinical practices pharmacovigilance schering plough remains committed accomplish work invest significant resources area like pharmaceutical companies scheringplough subject inspections fda emea regulatory authorities possible actions include demands improvements reporting systems criminal sanctions scheringplough andor responsible individuals changes conditions marketing authorizations scheringploughs products regulatory compliance postmarketing surveillance scheringplough engages clinical trial research many countries around world clinical trial research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities failure comply current good clinical practices applicable laws regulations result delays approval clinical trials suspension ongoing clinical trials delays approval marketing authorizations criminal sanctions scheringplough andor responsible individuals financial penalties changes conditions marketing authorizations scheringploughs products clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products addition situations raised concerns among prescribers patients relating safety efficacy pharmaceutical products general past several years occurrences increased intense media attention results enhance clinical trial led concerns among patients prescribers zetia vytorin see discussion item legal proceedings litigation investigations relating merckscheringplough cholesterol joint venture following wave product withdrawals companies significant safety issues health authorities fda emea pmda continued increase focus safety assessing benefitrisk balance drugs fda particular granted new legislative authority included several provisions focused drug safety pharmacovigilance including ability mandate labeling changes require postapproval evaluations studies addition health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties potential delays regulatory approval processes also continues significant regulatory legislative scrutiny especially us advertising promotion particular directtoconsumer advertising similarly major health authorities including fda emea pmda also increased collaboration amongst especially regard evaluation safety benefitrisk information media attention also increased current environment health authority regulatory action one market safety labeling change may regulatory prescribing marketing implications markets extent previously seen health authorities pmda japan publicly acknowledged significant backlog workload due resource constraints within agency backlog caused long regulatory review times new indications products added uncertainty predicting approval timelines markets pmda committed correcting backlog made progress last two years expected continue foreseeable future table contents us new presidential administration announced health care reform including regulation pharmaceutical companies products priority administration yet named health human services secretary fda commissioner may initiate change impact actions well budget pressures governments us nations predicted time uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect scheringploughs operations effect regulatory approval processes operations predicted scheringplough nevertheless achieved significant number important regulatory approvals since including approvals vytorin bridion europe noxafil clarinex clarinex reditabs clarinex suboxone new indications temodar nasonex significant approvals since include asmanex dpi dry powder inhalation us pegintron zetia temodar esmeroneslax nasonex ganirest japan new indications remicade schering plough also number significant regulatory submissions filed major markets awaiting approval including golimumab europe sugammadex us saphris asenapine us scheringploughs personnel regular open dialogue fda emea regulators review product labels materials regular basis new information becomes known pricing pressures described specifically note legal environmental regulatory matters item financial statements supplementary data pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs scheringplough also predict whether investigations affect marketing practices sales result could material adverse impact scheringploughs results operations cash flows financial condition business us many scheringploughs pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts instance third party payors use formulary restrictions control costs negotiating discounted prices exchange inclusion formulary change formulary status product may impact sales product us market scheringplough pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare resulted increased use generics increased purchasing power negotiating behalf medicare recipients international markets scheringplough operates environment government mandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs table contents since scheringplough unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals us effect operations cash flows reasonably estimated similarly effect operations cash flows future decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated competition market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted outlook scheringplough provide numeric guidance however following outlook may helpful readers assessing future prospects uncertainties financial credit markets along generally difficult business conditions contributed recently pressures companies us including pharmaceutical companies development economic effects along potential healthcare reforms federal state level us difficult predict scheringplough plans remain flexible managing business face challenges given current uncertainties cholesterol markets remains difficult predict longterm performance cholesterol franchise currently scheringplough believes us sales vytorin zetia expected lower international sales excluding impact foreign exchange continue grow full year scheringplough currently expects rd spending grow mid singledigit range risks set forth item risk factors k could cause actual results differ materially expectation provided section impact recently issued accounting standards september financial accounting standards board fasb issued statement financial accounting standards sfas fair value measurements standard defines fair value establishes framework measuring fair value accordance us generally accepted accounting principles expands disclosures fair value measurements standard codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions calendaryear companies standard became effective january see note fair value measurements item financial statements supplementary data except nonfinancial items measured nonrecurring basis effective beginning january implementation standard material impact scheringploughs financial statements based scheringploughs current financial position impact provisions standard effective january expected material february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement sfas permits table contents entities choose measure many financial instruments certain items fair value sfas also includes amendment sfas accounting certain investments debt equity securities applies entities availableforsale trading securities calendaryear companies standard became effective january scheringplough chose elect fair value option prescribed sfas result implementation standard material impact scheringploughs financial statements december fasb issued eitf issue accounting collaborative arrangements effective calendar year companies beginning january task force clarified manner costs revenues sharing payments made received partner collaborative arrangement presented income statement set forth certain disclosures required partners financial statements impact standard consolidated financial statements expected material december fasb issued sfas revised business combinations sfas r calendaryear companies standard applicable new business combinations occurring january sfas r requires acquiring entity recognize assets acquired liabilities assumed transaction acquisitiondate fair value limited exceptions significantly sfas r require acquisition costs generally expensed incurred certain acquired contingent liabilities recorded fair value acquired inprocess research development recorded fair value indefinitelived intangible asset acquisition date standard also impact certain unresolved matters related purchase transactions consummated prior effective date standard impact standard consolidated financial statements expected material standard may effect accounting future business combinations december fasb issued sfas noncontrolling interests consolidated financial statements amendment arb effective calendaryear companies beginning january standard establishes new accounting reporting standards noncontrolling interest subsidiary deconsolidation subsidiary impact standard consolidated financial statements expected material march fasb issued sfas disclosures derivative instruments hedging activities amendment fasb statement effective calendaryear companies beginning january standard enhances required disclosures regarding derivatives hedging activities impact standard consolidated financial statements expected material april fasb issued fasb staff position fsp fas determination useful life intangible assets fsp fsp amends factors considered developing renewal extension assumptions used determine useful life recognized intangible asset sfas goodwill intangible assets sfas fsp effective calendaryear companies beginning january requirement determining useful lives must applied prospectively intangible assets acquired effective date disclosure requirements must applied prospectively intangible assets recognized subsequent effective date impact standard consolidated financial statements expected material may fasb issued sfas hierarchy generally accepted accounting principles standard identifies sources accounting principles framework selecting principles used preparation financial statements presented conformity generally accepted accounting principles gaap united states gaap hierarchy sfas became effective november implementation standard material impact scheringploughs financial statements june fasb issued fsp eitf determining whether instruments granted sharebased payment transactions participating securities fsp addresses whether instruments granted sharebased payment transactions participating securities prior vesting therefore need included earnings allocation calculating earnings per share twoclass method described table contents sfas earnings per share fsp requires companies treat unvested sharebased payment awards nonforfeitable rights dividend dividend equivalents separate class securities calculating earnings per share fsp effective calendar year companies beginning january impact standard consolidated financial statements expected material october fasb issued fsp determining fair value financial asset market active fsp fsp clarified application sfas inactive market demonstrated fair value financial asset determined market financial asset inactive fsp effective upon issuance including prior periods financial statements issued implementation standard material impact scheringploughs financial statements december fasb issued fsp fas fin r disclosures public entities enterprises transfers financial assets interest variable interest entities fsp fas fin r requires enhanced disclosures transfers financial assets interests variable interest entities fsp effective interim annual periods ending december since fsp requires additional disclosures concerning transfers financial assets interest variable interest entities adoption fsp affect scheringploughs disclosures critical accounting policies estimates following accounting policies estimates considered significant changes certain judgments assumptions inherent policies could affect scheringploughs financial statements revenue recognition rebates discounts returns provision income taxes acquisitions impairment goodwill intangible assets property accounting pensions postretirement benefit plans accounting legal regulatory matters revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business revenue recognition also requires reasonable assurance collection sales proceeds recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process table contents revenue recognition new products based specific facts circumstances including estimated acceptance rates established products similar marketing characteristics absent ability make reliable estimates rebates discounts returns scheringplough would defer revenue recognition product discounts granted based terms arrangements wholesalers managed care organizations government purchasers certain market conditions rebates estimated based sales contract terms historical experience trend analysis projected market conditions various markets served scheringplough evaluates market conditions products groups products primarily analysis third party demand market research data well internally generated information data information provided purchasers obtained third parties subject inherent limitations accuracy validity sales returns estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition including expected generic introductions marketing matters specifically investigated analyzed part formulation return reserves scheringploughs agreements major us pharmaceutical wholesalers address number commercial issues product returns timing payment processing chargebacks quantity inventory held wholesalers respect quantity inventory held wholesalers agreements provide financial disincentive wholesalers acquire quantities product excess necessary meet current patient demand use agreements scheringplough expects avoid situations scheringploughs shipments product reflective current demand rebates discounts returns scheringploughs rebate accruals federal state governmental programs including medicaid medicare part december million million respectively commercial discounts returns rebate accruals december million million respectively accruals established period related revenue recognized resulting reduction sales establishment liabilities included total current liabilities case returns receivable adjustments allowance provided accounts receivable case governmental rebate programs scheringploughs payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy schering ploughs obligations additional information governmental inquiries focused part calculation rebates contained note legal environmental regulatory matters item financial statements supplementary data addition possible result governmental challenges changes interpretive guidance actual rebates could materially differ amounts accrued table contents following summarizes activity accounts related accrued rebates sales returns discounts ear ended ear ended december december dollars millions accrued rebatesreturnsdiscounts beginning period obss accruals acquired november provision rebates adjustment prioryear estimates payments provision returns purchaseaccounting adjustments adjustment prioryear estimates returns provision discounts adjustment prioryear estimates discounts granted accrued rebatesreturnsdiscounts end period year ended december purchase accounting adjustments reflect million related reversal return reserves recorded part purchase accounting obs reversal recorded reduction goodwill formulating recording accruals management utilizes assumptions estimates include historical experience wholesaler data projection market conditions estimated lag time sale payment rebate utilization estimates forecasted product demand amounts discussed critical accounting policy entitled revenue recognition part review accruals management performs sensitivity analysis considers differing assumptions subject judgment rebate accrual calculation based upon scheringploughs sensitivity analysis reasonably possible changes assumptions related rebate accruals could favorably unfavorably impact net sales income taxes annual amount consistent prior years sensitivity analysis excludes potential impacts specific matter involves interpretations statutes could favorable impact net sales income taxes future periods provision income taxes scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax table contents matters litigation see note legal environmental regulatory matters item financial statements supplementary data december total amount unrecognized tax benefits million million respectively includes tax liabilities well reductions deferred tax assets carrying full valuation allowance december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease next twelvemonth period approximately million would primarily attributable decision tax matter currently litigated newark district court decision yet rendered possible final resolution scheringploughs examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment receipt related cash dependent number factors many outside scheringploughs control scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations total amount interest expense related uncertain tax positions years ended december million million respectively total amount accrued interest related uncertain tax positions december million million respectively included accrued liabilities acquisitions impairment goodwill intangible assets property scheringplough accounts acquired businesses using purchase method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values consolidated financial statements results operations reflect acquired business completion acquisition cost acquire business including transaction costs allocated underlying net assets acquired business based respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired inprocess research development expensed date acquisition intangible assets amortized straightline basis expected life asset judgments made determining estimated fair value assigned class assets acquired liabilities assumed well asset lives materially impact results operations useful lives determined based expected future period benefit asset considers various characteristics asset including projected cash flows recoverability goodwill measured reporting unit level based twostep approach first carrying amount reporting unit compared fair value estimated future net discounted cash flows expected generated reporting unit extent carrying value reporting unit exceeds fair value reporting unit second step would performed whereby reporting units assets liabilities fair valued extent reporting units carrying value goodwill exceeds implied fair value goodwill impairment exists would recognized intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled billion billion december december respectively intangible assets goodwill increased significantly due acquisition obs annual amortization expense next five years estimated approximately million per year based intangible assets recorded december value assets subject continuing scientific medical marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment certain scheringploughs manufacturing sites operate capacity overall costs operating manufacturing sites significantly increased past several years due compliance activities scheringploughs manufacturing cost base relatively fixed actions part management table contents significantly reduce scheringploughs manufacturing infrastructure involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements management continues review carrying value certain manufacturing assets indications impairment future events decisions may lead additional asset impairments andor related costs accounting pension postretirement benefit plans pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions scheringplough assesses pension postretirement benefit plan assumptions regular basis evaluating assumptions scheringplough considers many factors including evaluation discount rate expected rate return plan assets healthcare cost trend rate retirement age assumption scheringploughs historical assumptions compared actual results analysis current market conditions asset allocations see note retirement plans postretirement benefits item financial statements supplementary data additional information discount rates used pension postretirement benefit plan calculations evaluated annually modified reflect prevailing market rates measurement date highquality fixed income debt instrument portfolio would provide future cash flows needed pay benefits included benefit obligations come due countries debt instruments thinly traded estimates based available market rates actuarial assumptions based upon managements best estimates judgment assumptions held constant increase basis points discount rate would estimated favorable impact million net pension postretirement benefit cost increase basis points expected rate return assumption would estimated favorable impact million net pension postretirement benefit cost assumptions held constant decrease basis points discount rate would estimated unfavorable impact million net pension postretirement benefit cost decrease basis points expected rate return assumption would estimated unfavorable impact million net pension postretirement benefit cost sensitivities based estimated net pension postretirement benefit cost includes annual impact obss plans expected rates return pension postretirement benefit plans represent average rates return earned plan assets period benefits included benefit obligation paid developing expected rate return scheringplough determines expected returns major asset classes principally equities fixed income real estate return expectations asset classes based assumptions economic growth inflation supported longterm historical data well scheringploughs actual experience return plan assets expected portfolio performance also reflects active management appropriate conditions worldwide debt equity markets deteriorated significantly conditions negative effect fair value plan assets unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based primarily calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ scheringploughs expected returns majority assets realized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees scheringploughs practice fund qualified pension plans least sufficient amounts meet minimum requirements set forth applicable laws scheringplough expects contribute approximately million retirement plans including approximately million us scheringplough retirement plan table contents targeted investment portfolio scheringploughs us retirement plan allocated percent equities percent fixed income investments percent real estate targeted investment portfolio scheringploughs us postretirement benefit plan allocated percent equities percent fixed income investments portfolios equity weightings consistent longterm nature plans benefit obligations nonus pension plans targeted investment portfolio varies based duration pension liabilities local governmental rules regulations substantially investments equities fixed income valued based quoted public market values investments real estate valued based periodic appraisals accounting legal regulatory matters management judgments estimates required accounting legal regulatory matters ongoing basis including insurance coverages scheringplough reviews status claims investigations legal proceedings ongoing basis time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs results operations cash flows financial condition market risk disclosure scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk scheringplough subsidiaries countries sales outside us accounted approximately percent global sales virtually sales denominated currencies local country scheringploughs reported sales profits cash flows exposed changing exchange rates date management deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact scheringploughs international operations widespread net assets scheringploughs international subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account separate component shareholders equity remaining international subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included statements consolidated operations occasion scheringplough used derivatives hedge specific foreign currency exposures part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options mitigate exposure event significant strengthening euro compared us dollar scheringplough purchased options aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accounting derivative instruments hedging activities amended sfas accordingly gain derivatives recognized statement consolidated operations december open foreign currency option contracts table contents scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income interest rate equity price risk financial assets exposed changes interest rates andor equity prices primarily cash equivalents shortterm investments debt equity securities held nonqualified trusts employee benefits assets totaled billion december cash equivalents shortterm investments percent decrease interest rates would decreased interest income approximately million securities held qualified nonqualified trusts due longterm nature liabilities trust assets fund scheringploughs exposure market risk deemed low financial obligations exposed variability interest rates primarily shortterm borrowings longterm floatingrate euro denominated term loan scheringplough longterm fixed rate debt outstanding percent decrease interest rates would increase fair value debt december approximately million scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments item financial statements supplementary data portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt december open interest rate swaps disclosure notice cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time scheringplough may contain forwardlooking statements within meaning private securities litigation reform act forwardlooking statements relate strictly historical current facts based current expectations forecasts future events identify forwardlooking statements use words anticipate believe could estimate expect forecast project intend plan potential similar words terms particular forwardlooking statements include statements relating future actions ability access capital markets pending acquisitions prospective products product approvals timing conditions regulatory approvals patent intellectual property protection future performance effectiveness marketed products pipeline drugs trends performance including trends cholesterol market sales efforts research development programs anticipated spending estimates rebates discounts returns expenses programs reduce expenses outcome contingencies litigation investigations growth strategy expected synergies financial results forwardlooking statements publications may turn wrong guarantees schering ploughs financial operational performance performance scheringploughs stock scheringplough assume obligation update forwardlooking statement many factors could cause actual results differ scheringploughs forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including table contents known although possible predict identify factors scheringplough refers item risk factors report scheringplough incorporates herein reference identification important factors respect risks uncertainties item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis financial condition results operations item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements report independent registered public accounting firm table contents scheringplough corporation subsidiaries statements consolidated operations amounts millions except per share figures fo r years e n ded december net sales cost sales selling general administrative research development acquired inprocess research development expenseincome net special acquisitionrelated charges equity income incomeloss income taxes cumulative effect change accounting principle income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss preferred stock dividends net incomeloss available common shareholders diluted earningsloss per common share earningsloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax diluted earningsloss per common share basic earningsloss per common share earningsloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle basic earningsloss per common share dividends per common share accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows amounts millions fo r years e n ded december operating activities net incomeloss cumulative effect change accounting principle net tax net incomeloss cumulative effect change accounting principle net tax adjustments reconcile net incomeloss cumulative effect change accounting principle net tax net cash provided operating activities depreciation amortization accrued sharebased compensation special acquisitionrelated charges payments gain sale divested products purchases derivative currency options change fair value currency options proceeds derivative instruments acquired inprocess research development payment us taxing authorities changes assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities income taxes payable foreign currency transaction exchange loss net net cash provided operating activities investing activities capital expenditures dispositions property equipment proceeds divested products net acquisition net cash acquired purchases shortterm investments maturities shortterm investments net net cash used investing activities financing activities cash dividends paid common shareholders cash dividends paid preferred shareholders proceeds preferred stock issuance net proceeds common stock issuance net paymentsissuance longterm debt net issuance costs payments shortterm borrowings stock option exercises net net cash used forprovided financing activities effect exchange rates cash cash equivalents net increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash paid interest net amounts capitalized cash paid income taxes see note accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets amounts millions except per share figures de ce mber assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt net current portion deferred income taxes longterm liabilities total longterm liabilities commitments contingent liabilities note shareholders equity mandatory convertible preferred shares par value per share face value issued december december common shares authorized shares par value issued december december paidin capital retained earnings accumulated comprehensive loss total less treasury shares cost total shareholders equity total liabilities shareholders equity accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity amounts millions ccumulated mandatory mandatory total convertible convertible compre share preferred preferred common paidin retained treasury hensive holders shares shares shares capital earnings shares loss equity balance january comprehensive income net income foreign currency translation minimum pension liability net tax per sfas unrealized gain investments available sale net tax total comprehensive income cash dividends common shares dividends preferred shares accrued dividends common shares adjustment pension postretirement liabilities upon adoption sfas net tax stock incentive plans balance december adoption fin net loss foreign currency translation pension otherpost retirement liabilities net tax derivative interest rate instruments unrealized gain investments available sale net tax total comprehensive loss issuance preferred stock issuance common stock conversion preferred stock sfas measurement date provisions net tax cash dividends common shares dividends preferred shares accrued dividends common shares stock incentive plans balance december net income foreign currency translation pension postretirement liabilities net tax derivative interest rate instruments unrealized loss investments available sale total comprehensive income dividends common shares dividends preferred shares stock incentive plans balance december accompanying notes integral part consolidated financial statements table contents notes consolidated financial statements summary significant accounting policies overview scheringplough innovationdriven sciencecentered global health care company biopharmaceutical research collaborations partners scheringplough creates therapies help save improve lives around world scheringplough applies research development platform prescription pharmaceutical consumer health care products well animal health products november scheringplough acquired organon biosciences nv obs company discovers develops manufactures human prescription animal health products see note acquisitions additional information principles consolidation consolidated financial statements include scheringplough corporation subsidiaries scheringplough intercompany balances transactions eliminated accounts obs included part scheringploughs results date acquisition november see note acquisition additional information use estimates preparation financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period ongoing basis scheringplough evaluates estimates based historical experience various assumptions believed reasonable circumstances actual results could differ estimates equity method accounting scheringplough accounts share activity merckscheringplough joint venture joint venture merck co inc merck using equity method accounting scheringplough significant influence joint ventures operating financial policies accordingly scheringploughs net sales include sales joint venture scheringploughs share earnings joint venture included equity income determining consolidated net incomeloss equity income joint venture included prescription pharmaceuticals segment revenue sales vytorin zetia recognized joint venture title risk loss passed customer reasonable assurance collection sales proceeds equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck see note equity income additional information regarding joint venture cash cash equivalents cash cash equivalents include operating cash highly liquid investments original maturities three months less including highly rated money market accounts shortterm investments shortterm investments carried fair value classified availableforsale investments consist certificates deposit commercial paper maturities less year table contents notes consolidated financial statements continued inventories inventories valued lower cost market cost determined using lastin firstout lifo method substantial portion inventories located us cost inventories determined firstin firstout method fifo depreciation property equipment depreciation provided estimated useful lives properties generally use straightline method useful lives property acquisitions generally follows asset category ears buildings building improvements equipment scheringplough reviews carrying value property equipment indications impairment accordance statement financial accounting standard sfas accounting impairment disposal longlived assets depreciation expense million million million depreciation expense included accelerated depreciation related manufacturing streamlining million foreign currency translation net assets scheringploughs international subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included comprehensive incomeloss reflected separate component shareholders equity remaining international subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included statements consolidated operations exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation account transactional exchange gains losses included expenseincome net revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business revenue recognition also requires reasonable assurance collection sales process table contents notes consolidated financial statements continued recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process earnings per common share diluted earningsloss per common share computed dividing net incomeloss available common shareholders plus preferred stock dividends dilutive effect mandatory convertible preferred stock sum weighted average number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options dilutive effect shares issuable upon conversion scheringploughs mandatory convertible preferred stock basic earningsloss per common share computed dividing net incomeloss available common shareholders weighted average number common shares outstanding goodwill intangible assets financial accounting standards board fasb sfas goodwill intangible assets requires intangible assets acquired either individually group assets initially recognized measured based fair value intangible finite life amortized useful life intangible indefinite life including goodwill amortized company assesses recoverability carrying value goodwill intangible assets indefinite useful lives annually whenever events changes circumstances indicate carrying amount asset may fully recoverable recoverability goodwill measured reporting unit level based twostep approach first carrying amount reporting unit compared fair value estimated future net discounted cash flows expected generated reporting unit extent carrying value reporting unit exceeds fair value reporting unit second step would performed whereby reporting units assets liabilities fair valued extent reporting units carrying value goodwill exceeds implied fair value goodwill impairment exists would recognized recoverability intangible assets indefinite useful lives measured comparison carrying amount intangible assets fair value respective intangible assets excess carrying value intangible assets fair value intangible assets would recognized impairment loss scheringplough conducts annual impairment testing goodwill october year based impairment tests performed impairment goodwill scheringploughs goodwill intangible asset balances increased significantly due acquisition obs see note acquisition note goodwill intangible assets additional information assets included assets capitalized software million million december respectively amortization expense million million million respectively assets december included million restricted cash primarily letter credit related certain international tax matters table contents notes consolidated financial statements continued income taxes scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january fin order recognize uncertain tax benefit taxpayer must likely sustaining position measurement benefit calculated largest amount percent likely realized upon resolution position scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations deferred income taxes recognized future tax effects temporary differences financial income tax reporting basis scheringploughs assets liabilities based enacted tax laws rates accounting sharebased compensation prior january scheringplough accounted stockbased compensation arrangements using intrinsic value method sharebased employee compensation cost reflected statements consolidated operations scheringploughs deferred stock units performance plans stock options granted plans exercise price equal market value underlying common stock date grant effective january scheringplough accounts sharebased compensation accordance sfas revised sharebased payment sfas r see note sharebased compensation additional information shipping handling expenses shipping expenses classified selling general administrative expenses consolidated statement operations impact recently issued accounting pronouncements september fasb issued sfas fair value measurements standard defines fair value establishes framework measuring fair value accordance us generally accepted accounting principles expands disclosures fair value measurements standard codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions calendaryear companies standard became effective january see note fair value measurements except nonfinancial items measured nonrecurring basis effective beginning january implementation standard material impact scheringploughs financial statements based scheringploughs current financial position impact provisions standard effective january expected material february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement sfas permits entities choose measure many financial instruments certain items fair value sfas also includes amendment sfas accounting certain investments debt equity securities applies entities availableforsale trading securities calendaryear companies standard became effective january scheringplough chose elect fair value option prescribed sfas result implementation standard material impact scheringploughs financial statements table contents notes consolidated financial statements continued december fasb issued eitf issue accounting collaborative arrangements effective calendar year companies beginning january task force clarified manner costs revenues sharing payments made received partner collaborative arrangement presented income statement set forth certain disclosures required partners financial statements impact standard consolidated financial statements expected material december fasb issued sfas revised business combinations sfas r calendaryear companies standard applicable new business combinations occurring january sfas r requires acquiring entity recognize assets acquired liabilities assumed transaction acquisitiondate fair value limited exceptions significantly sfas r require acquisition costs generally expensed incurred certain acquired contingent liabilities recorded fair value acquired inprocess research development recorded fair value indefinitelived intangible asset acquisition date standard also impact certain unresolved matters related purchase transactions consummated prior effective date standard impact standard consolidated financial statements expected material standard may effect accounting future business combinations december fasb issued sfas noncontrolling interests consolidated financial statements amendment arb effective calendaryear companies beginning january standard establishes new accounting reporting standards noncontrolling interest subsidiary deconsolidation subsidiary impact standard consolidated financial statements expected material march fasb issued sfas disclosures derivative instruments hedging activities amendment fasb statement effective calendaryear companies beginning january standard enhances required disclosures regarding derivatives hedging activities impact standard consolidated financial statements expected material april fasb issued fasb staff position fsp fas determination useful life intangible assets fsp fsp amends factors considered developing renewal extension assumptions used determine useful life recognized intangible asset sfas fsp effective calendaryear companies beginning january requirement determining useful lives must applied prospectively intangible assets acquired effective date disclosure requirements must applied prospectively intangible assets recognized subsequent effective date impact standard consolidated financial statements expected material may fasb issued sfas hierarchy generally accepted accounting principles standard identifies sources accounting principles framework selecting principles used preparation financial statements presented conformity generally accepted accounting principles gaap united states gaap hierarchy sfas became effective november implementation standard material impact scheringploughs consolidated financial statements june fasb issued fsp eitf determining whether instruments granted sharebased payment transactions participating securities fsp addresses whether instruments granted sharebased payment transactions participating securities prior vesting therefore need included earnings allocation calculating earnings per share twoclass method described sfas earnings per share fsp requires companies treat unvested sharebased payment awards non forfeitable rights dividend dividend equivalents separate class securities calculating earnings per share fsp effective calendaryear companies beginning january impact standard consolidated financial statements expected material table contents notes consolidated financial statements continued october fasb issued fsp determining fair value financial asset market active fsp fsp clarified application sfas inactive market demonstrated fair value financial asset determined market financial asset inactive fsp effective upon issuance including prior periods financial statements issued implementation standard material impact scheringploughs consolidated financial statements december fasb issued fsp fas fin r disclosures public entities enterprises transfers financial assets interest variable interest entities fsp fas fin r requires enhanced disclosures transfers financial assets interests variable interest entities fsp effective interim annual periods ending december since fsp requires additional disclosures concerning transfers financial assets interest variable interest entities adoption fsp affect scheringploughs disclosures acquisition scheringplough acquired obs purchase price approximately euro billion cash approximately billion including legal professional fees november acquisition date acquisition added diversification marketed products including two new therapeutic areas womens health central nervous system well significant strength animal health products rd pipeline purchase method accounting used account transaction accordance sfas business combinations operating results obs included scheringploughs consolidated financial statements period subsequent acquisition date following table provides unaudited pro forma financial information years ended december acquisition occurred beginning period presented dollars millions except per share data unaudited net sales net loss cumulative effect change accounting principle net loss available common shareholders diluted loss per common share basic loss per common share unaudited pro forma financial information periods presented includes amortization stepup inventory billion acquired inprocess research development charge billion nonrecurring charges directly attributable accounting acquisition unaudited pro forma financial information also includes effect purchase accounting adjustments additional amortization expense acquired identifiable intangible assets depreciation stepup property effect given unaudited pro forma financial information synergistic benefits may realized costs related integration obs unaudited pro forma financial information considered indicative actual results would achieved acquisition consummated dates indicated purport indicate results operations future date future period preliminary allocation purchase price obs made acquisition date final allocation purchase price resulted net decrease goodwill million compared preliminary allocation acquisition date adjustment preliminary purchase price allocation primarily related updated valuations identifiable intangible assets property inventories well table contents notes consolidated financial statements continued updates acquired liabilities deferred taxes final allocation purchase price obs follows ollars millions cash current assets excluding inventories inventories property identifiable intangible assets goodwill othernon current assets acquired inprocess research development iprd total assets acquired acquisition related liabilities current liabilities deferred tax liabilities othernon current liabilities total liabilities assumed net assets acquired final purchase price allocation identifiable intangible assets follows w eightedaverage amortization amount period years dollars millions patents womens health contraception womens health fertility womens health central nervous system human prescription pharmaceuticals total patents trademarks animal health prescription pharmaceuticals total trademarks total intangible assets acquired weightedaverage life total acquired intangible assets approximately years intangible assets significant residual value acquired intangible assets determined indefinite life billion goodwill assigned prescription pharmaceuticals segment million assigned animal health segment none goodwill deductible income tax purposes table contents notes consolidated financial statements continued billion assigned acquired iprd charged operations fourth quarter charge associated research projects animal health research projects womens health central nervous system anesthesia therapeutic areas human health amount determined using discounted cash flow projections identified research projects technological feasibility established alternative future use discount rates used ranged percent percent projected launch dates following us food drug administration fda regulatory approval years time scheringplough expects projects begin generate cash flows cost complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated cost complete projects near final stages development excess million research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda regulatory approvals included acquisition related liabilities costs exit certain activities obs conjunction obs acquisition scheringplough agreed divest certain assets part regulatory reviews us europe see note expenseincome net special acquisition related charges manufacturing streamlining special acquisitionrelated charges special acquisitionrelated charges relate productivity transformation program ptp activities include ongoing integration obs business see note obs integration productivity transformation program additional information special acquisitionrelated charges million costs included million employee termination costs remaining charges related integration activities special acquisitionrelated charges year ended december scheringplough incurred million special acquisitionrelated charges comprised million integrationrelated costs obs acquisition million employee termination costs part integration activities manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamlined global supply chain enhanced scheringploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new jersey special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico table contents notes consolidated financial statements continued following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed charges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december severance accrued liability december obs integration productivity transformation program part purchase price allocation obs acquisition acquisition date scheringplough recorded acquisitionrelated liabilities million related involuntary termination benefits april scheringplough announced major new program productivity transformation program ptp includes ongoing integration obs designed reduce avoid costs increase productivity targeted savings envisioned program include resulting previously announced obs integration synergies following table summarizes charges cash payments liabilities related productivity transformation program includes ongoing integration obs december acqu ition related liabilities employee employee termination termination exit costs costs costs dollars millions accrued liability december chargesa purchase price allocation itemsb cash payments accrued liability december recorded special acquisitionrelated charges b recorded part purchase accounting included acquisitionrelated liabilities december costs exit certain activities obs equity income may scheringplough merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma table contents notes consolidated financial statements continued drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy managed zetia us asia ezetrol europe ii coadministration various approved statin drugs iii fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin managed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched many international markets scheringplough utilizes equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringploughs net sales include sales joint venture cholesterol joint venture agreements provide sharing operating income generated joint venture based upon percentages vary product sales level country us market scheringplough receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough generally share profits equally scheringploughs allocation joint venture income increased milestones recognized either companys share joint ventures income operations subject reduction company fails perform specified minimum number physician details particular country companies agree annually minimum number physician details country companies bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement company physician details set annual basis italy contractual amount included profit sharing calculation reimbursed us canada puerto rico amount equal companys agreed physician details multiplied contractual fixed fee scheringplough reports amounts part equity income cholesterol joint venture amounts represent reimbursement specific incremental identifiable costs schering ploughs detailing cholesterol products markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher costs joint venture companies contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally scheringplough merck allergyasthma agreements provided joint development marketing companies oncedaily fixedcombination tablet containing loratadinemontelukast april merckscheringplough joint venture received notapprovable letter fda proposed fixed combination loratadinemontelukast second quarter respiratory joint venture terminated accordance agreements action impact cholesterol joint venture result table contents notes consolidated financial statements continued termination respiratory joint venture schering plough received payments totaling million scheringplough recognized equity income following information provides summary components scheringploughs equity income cholesterol joint venture years ended december dollars millions scheringploughs share net income including milestones million contractual amounts physician details elimination intercompany profit net total equity income merckscheringplough joint venture december scheringplough net receivables including undistributed income merckscheringplough joint venture million million respectively equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck due virtual nature cholesterol joint venture scheringplough incurs substantial costs selling general administrative costs reflected equity income borne overall cost structure scheringplough costs reported respective line items statements consolidated operations separately identifiable cholesterol agreements provide jointly owned facilities products resulting joint venture manufactured facilities owned either scheringplough merck scheringplough merck developing singletablet combination ezetimibe atorvastatin treatment elevated cholesterol levels see note legal environmental regulatory matters litigation investigations relating merckscheringplough cholesterol joint venture sharebased compensation prior january scheringplough accounted stock compensation arrangements using intrinsic value method followed recognition measurement principles apb opinion accounting stock issued employees related interpretations prior stockbased employee compensation cost reflected statement consolidated operations scheringploughs deferred stock units stock options granted plans exercise price equal market value underlying common stock date grant scheringplough adopted sfas r effective january sfas r requires companies recognize compensation expense amount equal fair value sharebased payments granted employees scheringplough elected modified prospective transition method therefore adjustments prior periods required result adopting sfas r method provisions sfas r apply awards granted date adoption unrecognized expense awards unvested date adoption based grant date fair value sfas r also amended sfas statement cash flows require excess tax benefits reflected operating cash flows reflected financing cash flows grants issued retirementeligible employees prior adoption sfas r scheringplough recognized compensation costs stated vesting period stock option deferred stock unit acceleration unrecognized compensation costs upon retirement employee upon adoption table contents notes consolidated financial statements continued sfas r scheringplough recognizes compensation costs sharebased grants made january service period earlier one year employee becomes retirementeligible first year grant ii employees retirement eligibility date first year grant iii service period award november fasb issued fasb staff position fas r transition election related accounting tax effects sharebased payment awards scheringplough elected adopt transition method provided fasb staff position purposes calculating pool excess tax benefits available absorb tax deficiencies recognized subsequent adoption sfas r stock incentive plan plan approved scheringploughs shareholders terms plan million scheringploughs authorized common shares may granted stock options awarded deferred stock units officers certain employees scheringplough december scheringplough intends utilize unissued authorized shares satisfy stock option exercises issuance deferred stock units expenses related sharebased compensation classified line item associated employees function scheringplough granted performancebased deferred stock units stock incentive plan provide certain senior managers opportunity earn shares scheringplough common stock units earned specific preestablished levels performance service achieved applicable threeyear performance period implementation sfas r first quarter scheringplough recognized benefit income million cumulative effect change accounting principle related two longterm compensation plans required accounted liability plans sfas r tax benefits recognized related stockbased compensation related cash flow impacts material scheringplough us net operating loss position stock options stock options granted employees exercise prices equal fair market value scheringploughs stock dates grant stock options plan generally vest three years term seven years certain options granted previous plans vest longer periods ranging three nine years term years compensation costs stock options recognized requisite service period separately vesting portion stock option award expense recognized net estimated forfeitures vesting period options using accelerated method expense recognized approximately million million million respectively weightedaverage assumptions used blackscholes optionpricing model follows dividend yield volatility riskfree interest rate expected term options years dividend yields based historical dividend yields expected volatilities based historical volatilities scheringploughs common stock expected differ materially future table contents notes consolidated financial statements continued volatility riskfree interest rate based us treasury yield curve effect time grant periods corresponding expected life options expected term options represents weighted average period time options granted expected outstanding giving consideration vesting schedules scheringplough utilizes simplified method calculating expected term stock options allowed staff accounting bulletin sab amended sab historical experience expected reasonable basis estimated expected term due various changes business amount cash received exercise stock options million million million respectively summarized information stock options outstanding exercisable december follows ou tstanding exerc able weighted weighted weighted number average average number average remaining exercise exercise exercise price range options term years price options price thousands thousands weightedaverage fair value stock options granted respectively intrinsic value stock options exercised million million million respectively total fair value options vested million million million respectively december total remaining unrecognized compensation cost related nonvested stock options amounted million amortized weightedaverage remaining requisite service period years following table summarizes stock option activity december changes year ended current prior plans w eighted number average exercise options price thousands outstanding january granted exercised canceled expired outstanding december exercisable december aggregate intrinsic value stock options outstanding december million aggregate intrinsic value stock options currently exercisable december million intrinsic value stock options calculated based exercise price underlying awards quoted price scheringploughs common stock reporting date table contents notes consolidated financial statements continued following table summarizes nonvested stock option activity december changes year ended current prior plans w eighted average number fair options value thousands nonvested january granted vested forfeited nonvested december deferred stock units fair value deferred stock units determined based number shares granted quoted price scheringploughs common stock date grant deferred stock units generally vest end three years provided employee remains service scheringplough expense recognized straightline basis vesting period deferred stock units payable equivalent number common shares expense recognized million million million respectively summarized information deferred stock units outstanding december follows ou tstanding weighted number average weighted deferred remaining average deferred stock unit price range stock units term years fair value thousands weightedaverage fair value deferred stock units granted respectively total fair value deferred stock units vested million million million respectively december total remaining unrecognized compensation cost related deferred stock units amounted million amortized weightedaverage remaining requisite service period years table contents notes consolidated financial statements continued following table summarizes deferred stock unit activity december changes year ended current prior plans number nonvested weighted deferred average stock units fair value thousands nonvested january granted vested forfeited nonvested december performancebased deferred stock units distribution performancebased deferred stock units contingent scheringplough meeting either performance andor market conditions one half performancebased stock unit grant performance condition fair value units based closing stock price date grant half grant market condition fair value units determined using lattice valuation model expected volatility assumptions assumptions appropriate determining fair value compensation expense performancebased stock units excludes dividend equivalents based fair values awards expected vest based performance measures recognized performance period total compensation expense recognized years ended million million respectively weighted average grantdate fair value performancebased deferred stock units granted respectively represented approximately underlying shares respectively december none units vested december unrecognized compensation cost related deferred stock units million amortized remaining weighted average requisite service period years remaining unrecognized compensation cost performance based deferred stock units may vary reporting period based changes expected achievement performance measures following table summarizes performancebased deferred stock unit activity december changes year ended number nonvested performancebased weighted deferred stock average units fair value thousands nonvested january granted vested forfeited nonvested december liability plans scheringplough two compensation plans performance vesting periods ended december plans classified liability plans sfas r ultimate cash payout plans based scheringploughs stock performance compared stock table contents notes consolidated financial statements continued performance peer group upon adoption sfas r january scheringplough recognized cumulative income effect change accounting principle million order recognize liability plans fair value service period income expense amounts related liability plans based change fair value reporting date fair value plans prior end service period estimated using lattice valuation model using expected volatility assumptions assumptions appropriate determining fair value first liability plans service period concluded december value plan became fixed second liability plans service period concluded december income expense recognized liability plans statements consolidated operations exclusive impact cumulative effect change accounting principle income million expense million million respectively december remaining unrecognized compensation cost related liability plans expenseincome net components expenseincome net follows dollars millions interest cost incurred less amount capitalized construction interest expense interest income foreign exchange lossesgains net gain sale divested products realized gain foreign currency options net ineffective portion interest rate swaps net total expenseincome net september scheringplough completed previously announced divestitures certain animal health products required regulatory agencies us europe connection acquisition obs result divestitures scheringplough recognized gain million million tax addition scheringplough recognized gain million million tax sale manufacturing site net cash proceeds divested animal health products million scheringplough participated health care refinancing programs adopted local government fiscal authorities major european market scheringplough transferred million million respectively trade accounts receivables owned foreign subsidiary thirdparty financial institutions without recourse transfer trade accounts receivable qualified sales accounts receivable sfas accounting transfers servicing financial assets extinguishments liabilities transfer trade accounts receivable material impact schering ploughs statements consolidated operations cash flows transactions included change accounts receivable operating activities net foreign exchange gains million includes million foreign currency transaction exchange losses related euro denominated debt instruments prior accounted economic hedges net investment foreign operation currency exchange losses noncash items table contents notes consolidated financial statements continued included adjustments reconcile net loss net cash provided operating activities statement consolidated cash flows part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options derivatives aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accounting derivative instruments hedging activities amended sfas accordingly gain derivatives recognized statement consolidated operations derivatives shortterm trading nature hedge specific financing investing transaction accordingly cash impacts derivatives classified operating cash flows statement consolidated cash flows derivatives terminated fourth quarter scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest rate payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt cash flow impacts interest rate swaps classified operating cash flows statement consolidated cash flows income taxes components consolidated incomeloss income taxes years ended december follows dollars millions united states foreign net incomeloss income taxes including cumulative effect change accounting principle net incomeloss include amortization fair values certain assets acquired part obs acquisition net loss includes charge acquired inprocess research development billion connection acquisition obs income cholesterol joint venture included table based jurisdiction income earned table contents notes consolidated financial statements continued components income tax expense years ended december follows fe deral tate fo reign otal dollars millions current deferred total current deferred total current deferred total scheringplough established valuation allowance net us deferred tax assets including benefit us operating losses management concluded likely benefit us net deferred tax assets realized december scheringplough continues maintain valuation allowance us net deferred tax assets scheringplough maintains intent indefinitely reinvest earnings international subsidiaries scheringplough provided deferred taxes approximately billion undistributed foreign earnings december determining tax liability would arise earnings remitted practicable liability would depend number factors including amount earnings distributed whether us operations generating taxable profits losses deferred income taxes provided temporary differences financial reporting basis tax basis scheringploughs assets liabilities scheringploughs deferred tax assets result principally recording certain items currently deductible tax purposes net operating loss tax credit carryforwards scheringploughs deferred tax liabilities principally result book tax basis differences resulting obs acquisition use accelerated depreciation tax purposes table contents notes consolidated financial statements continued components scheringploughs deferred tax assets liabilities december follows dollars millions deferred tax assets nol carryforwards tax credit carryforwards postretirement employee benefits inventory related sales return reserves litigation accruals intangible assets total deferred tax assets deferred tax liabilities depreciation inventory valuation obs intangible assets total deferred tax liabilities deferred tax valuation allowance net deferred tax liabilities deferred tax assets net operating losses tax credit carryforwards principally relate us nols research development rd tax credits us foreign tax credits federal alternative minimum tax amt credit carryforwards december scheringplough approximately billion us nols income tax purposes available offset future us taxable income us nols us operating losses adjusted differences financial tax reporting us nols expire varying amounts unused state nols related us nols expire varying amounts december scheringplough approximately million rd tax credits carryforwards expire million foreign tax credit carryforwards expire million amt tax credit carryforwards indefinite life us nol carryforward could materially reduced examination scheringploughs income tax returns internal revenue service irs scheringplough reduced deferred tax assets related valuation allowance recorded us nols tax credit carryforwards reflect estimated resolution examinations table contents notes consolidated financial statements continued difference income taxes based us statutory tax rate scheringploughs income tax expense years ended december due following dollars millions income tax expensebenefit us statutory rate increasedecrease taxes resulting lower rates jurisdictions net us operating losses tax benefit recorded permanent differences state income tax provision tax matters income tax effective tax rate permanent differences largely attributable acquired inprocess research development charge billion related acquisition obs tax benefit recorded lower tax rates jurisdictions net primarily attributable scheringploughs manufacturing subsidiaries singapore ireland puerto rico operate various incentive tax grants begin expire additionally major countries schering plough conducts operations statutory tax rates less us tax rate overall income taxes primarily relate foreign taxes include benefit related us operating losses scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax matters litigation see note legal environmental regulatory matters december total amount unrecognized tax benefits million million respectively includes tax liabilities well reductions deferred tax assets carrying full valuation allowance december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease next twelvemonth period approximately million would primarily attributable decision tax matter currently litigated newark district court decision yet rendered possible final resolution scheringploughs examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment receipt related cash dependent number factors many outside scheringploughs control scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations total amount interest expense related uncertain tax positions years ended december million million respectively total amount accrued interest related uncertain tax positions december million million respectively included accrued liabilities table contents notes consolidated financial statements continued tabular reconciliation scheringploughs fin unrecognized tax benefits years ended december follows dollars millions january additions tax positions related current year additions tax positions related prior years additions tax positions related acquired entities reductions related amounts settled taxing authorities reductions tax positions related prior years reductions potential refund claims december scheringplough considering filing refund claims based court decisions involving claim right doctrine two courts appeal decisions clarifying law area made clear scheringplough would prevail claims amount unrecognized tax benefits reduced accordingly impact net loss net consolidated income tax payments exclusive payments related tax examinations litigation discussed million million million respectively second quarter irs completed examination scheringploughs federal income tax returns schering plough seeking resolution issue raised examination irs administrative appeals process july schering plough made payment million irs pertaining examination scheringplough remains open irs tax years irs commenced examination federal income tax returns examination expected completed significant tax jurisdictions us state foreign scheringploughs income tax returns open examination period october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation tried newark district court decision yet rendered scheringploughs tax reserves adequate cover abovementioned payments retirement plans postretirement benefits plan descriptions scheringplough defined benefit pension plans covering eligible employees us certain foreign countries largest us plan scheringplough retirement plan benefits normal retirement primarily based upon participants average final earnings years service social security income modified early retirement death disability benefits also available plan benefits become fully vested five years service plan provides continued accrual table contents notes consolidated financial statements continued credited service employees opt postpone retirement remain employed scheringplough reaching normal retirement age largest international definedbenefit plan dutch plan scheringplough pension fund provides benefits normal retirement age based primarily participants average earnings years service benefit takes account social security equivalent income postponement retirement option local dutch regulation benefits modified early retirement death disability benefits also available plan nonus pension plans offer benefits competitive local market conditions defined benefit plans assumed scheringplough part obs acquisition included scheringploughs consolidated results operations consolidated financial position acquisition date financial position december see note acquisition addition scheringplough provides postretirement medical life insurance benefits primarily eligible us retirees dependents postretirement benefit plans certain countries also provide postretirement benefit plans effective december scheringplough accounts retirement plans postretirement benefit plans plans accordance sfas employers accounting defined benefit pension postretirement plans sfas sfas requires recognition asset overfunded plans liability underfunded plans scheringploughs consolidated balance sheets statement also requires recognition changes funded status plans year changes occur scheringploughs definedbenefit pension postretirement plans december measurement date included scheringploughs accumulated comprehensive loss december billion billion net tax effects million million net tax effects respectively costs recognized components net periodic benefit costs pursuant sfas employers accounting pensions sfas employers accounting postretirement benefits pensions components costs december follows oth e r pos retirement retirement plans benefits dollars millions actuarial loss prior service costcredit total actuarial losses primarily represent cumulative difference actuarial assumptions actual returns plan assets changes discount rates plans experience total loss amounts net excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amounts accumulated comprehensive loss expected recognized components net periodic costs follows retirement postretirement plans benefits dollars millions actuarial loss recognition prior service costcredit recognition table contents notes consolidated financial statements continued actuarial assumptions consolidated weighted average assumptions used determine benefit obligations december ret ir emen othe r postr etireme nt plans benefits us benefit plans discount rate rate increase future compensation na na international benefit plans discount rate rate increase future compensation na na scheringploughs international postretirement benefit plans argentina brazil canada south africa assumptions used develop benefit obligations yearend consolidated weighted average assumptions used determine net benefit costs years ended december ot h e r pos tre ir emen retirement plans benefits us benefit plans discount rate longterm expected rate return plan assets rate increase future compensation na na na international benefit plans discount rate longterm expected rate return plan assets na na na rate increase future compensation na na na assumptions used determine net periodic benefit costs year established end previous year assumptions used determine benefit obligations established yearend net periodic benefit costs actuarial present value benefit obligations based actuarial assumptions determined annually based evaluation longterm trends well market conditions may impact cost providing retirement benefits longterm expected rates return plan assets derived return assumptions determined major asset classes equities fixed income real estate proportional basis return expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weighted average assumed healthcare cost trend rate used postretirement measurement purposes percent trending percent percent increase assumed healthcare cost trend rate would increase combined postretirement service interest cost million postretirement benefit obligation million percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assumed based annual rates retirement experienced scheringplough table contents notes consolidated financial statements continued components net periodic benefit costs net pension postretirement periodic benefit costs totaled million million million respectively components net pension postretirement periodic benefit costs follows pos tre tir ement retirement plans benefits dollars millions service cost interest cost expected return plan assets amortization net termination benefits settlements net pension postretirement periodic benefit costs net pension postretirement periodic benefit cost attributable us retirement postemployment benefit plans million million million benefit obligations components changes benefit obligations follows ther po tretir ement retirement plans benefits dollars millions benefit obligations beginning year service cost interest cost medicare drug subsidy received participant contributions effects exchange rate changes benefits paid acquisitionsplan transfers actuarialgainslosses including assumption change change measurement date plan amendments termination benefits curtailment settlement benefit obligations end year benefit obligations overfunded plans benefit obligations underfunded plans benefit obligations us plans retirement benefits postretirement benefits billion billion table contents notes consolidated financial statements continued funded status balance sheet presentation components changes plan assets follows ther po tretir ement retirement plans benefits dollars millions fair value plan assets primarily stocks bonds beginning year actual lossgain plan assets employer contributions participant contributions acquisitionsplan transfers change measurement date effects exchange rate changes settlements benefits paid fair value plan assets end year plan assets overfunded plans plan assets underfunded plans fair value us pension postretirement benefits plan assets billion billion reduction fair value plan assets december compared december due conditions worldwide debt equity markets deteriorated significantly conditions negative effect fair value plan assets addition plan assets indicated december securities investments million million respectively held nonqualified trust designated provide pension benefits certain underfunded plans accordance sfas december net asset overfunded plans million million respectively related scheringploughs retirement plans included longterm assets accompanying consolidated balance sheets net liability underfunded plans december totaled billion billion respectively follows ther po tretir ement retirement plan benefits dollars millions accrued compensation current longterm liabilities total december accumulated benefit obligations abo retirement plans billion billion respectively aggregated accumulated benefit obligations fair values plan assets retirement plans accumulated benefit obligations excess plan assets table contents notes consolidated financial statements continued billion billion respectively december billion billion respectively december plan assets fair value asset allocation consolidated retirement plans december target allocation follows per ce ntage target plan assets allocation december asset category equity securities debt securities real estate total asset allocation postretirement benefit trusts december target allocation follows per ce ntage target plan assets allocation december asset category equity securities debt securities total scheringploughs investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns consistent acceptable level overall portfolio market value risk assets periodically rebalanced back target allocations estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid r etirement ther postretirement plans benefits dollars millions years scheringploughs practice fund qualified pension plans least sufficient amounts meet minimum requirements set forth applicable laws scheringplough expects contribute approximately million retirement plans including approximately million us scheringplough retirement plan table contents notes consolidated financial statements continued defined contribution plans scheringplough maintains defined contribution savings plans us including plan acquired part obs acquisition largest us plan scheringplough makes contributions plan equal percent eligible employee earnings plus matching contribution percent eligible employee earnings based employee contributions total scheringplough contributions plans million million million respectively scheringplough also maintains defined contribution retirement plans various jurisdictions scheringploughs contributions plans material earningsloss per common share following table reconciles components basic diluted earningsloss per share computations dollars shares millions eps numerator net incomeloss available common shareholders eps denominator weighted average shares outstanding basic eps dilutive effect options deferred stock units average shares outstanding diluted eps years ended december approximately million common shares obtainable upon conversion mandatory convertible preferred stock excluded computation diluted earningsloss per common share effect would antidilutive third quarter scheringploughs mandatory convertible preferred stock converted million common shares common shares included weighted average shares calculation period conversion years ended december million million common shares respectively obtainable upon conversion mandatory convertible preferred stock excluded computation diluted earningsloss per common share effect would antidilutive weighted average basis period prior conversion common shares issuable scheringploughs stock incentive plans excluded computation diluted earningsloss per common share antidilutive effect would million million million respectively years ended december respectively scheringplough issued common shares august common shares included weightedaverage shares calculation period issuance see note shareholders equity additional information table contents notes consolidated financial statements continued accumulated comprehensive loss components accumulated comprehensive loss december follows dollars millions foreign currency translation adjustment pension postretirement liabilities net tax effects accordance sfas provisions accumulated derivative loss unrealized lossgain investments available sale net tax total included foreign currency translation adjustment gains million loss million respectively scheringploughs eurodenominated debt instruments designated effective economic hedges net investment foreign operation scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest rate payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt years ended december million million respectively effective portion interest rate swaps recognized interest expense million expected recognized interest expense gross unrealized pretax loss investments million gain million inventories inventories consisted following december dollars millions finished products goods process raw materials supplies total inventories inventory classified noncurrent assets overall decrease total inventories primarily due amortization fair value stepup recorded part obs acquisition million million respectively included depreciation amortization consolidated statements cash flows included assets december million million respectively inventory expected sold within one year inventories valued lastin firstout lifo basis comprised approximately percent percent total inventories december respectively estimated replacement cost total inventories december billion billion respectively cost inventories determined firstin firstout method fifo table contents notes consolidated financial statements continued goodwill intangible assets part purchase accounting acquisition obs scheringplough recorded billion goodwill billion assigned prescription pharmaceuticals segment million assigned animal health segment none goodwill related obs acquisition deductible income tax purposes following table summarizes goodwill activity years ending december consumer consumer prescription animal health prescription animal health pharmaceuticals health care total pharmaceuticals health care total dollars millions goodwill balance january acquisitions foreign exchange adjustments obs purchase accounting goodwill balance december components intangible assets net follows december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net dollars millions patents trademarks licenses total intangible assets patents trademarks licenses amortized straightline method respective useful lives residual value intangible assets estimated zero part purchase accounting acquisition obs scheringplough recorded billion intangible assets see note acquisition additional information amortization expense related intangible assets million million million respectively included cost sales statement consolidated operations intangible assets reviewed determine recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review annual amortization expenses related intangible assets years expected approximately million product licenses december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending scheringploughs rights exclusively market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits scheringploughs distribution products scheringplough marketing territory table contents notes consolidated financial statements continued share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products conditioned approval golimumab granted prior september scheringplough may independently develop market golimumab crohns disease indication territories option centocor participate addition scheringplough centocor agreed utilize autoinjector device commercialization golimumab agreed share development costs rights device scheringplough made upfront payment million included research development expenses accompanying statement consolidated operations year ended december borrowings commitments short longterm borrowings scheringploughs outstanding borrowings december follows dollars millions shortterm commercial paper shortterm borrowings current portion longterm debt current portion capital leases total shortterm borrowings longterm senior unsecured eurodenominated notes due floating rate unsecured eurodenominated term loan due senior unsecured notes due senior unsecured eurodenominated notes due senior unsecured notes due senior unsecured notes due senior unsecured notes due capital leases longterm borrowings total longterm borrowings scheringploughs shortterm borrowings consist primarily bank loans commercial paper issued us weighted average interest rate shortterm borrowings percent percent december respectively senior unsecured notes october scheringplough issued euro million aggregate principal amount percent senior unsecured euro denominated notes due euro billion aggregate principal amount percent senior unsecured eurodenominated notes due net proceeds offering approximately billion interest notes payable annually effective interest rate percent senior unsecured eurodenominated notes percent senior unsecured eurodenominated notes incorporates initial discount debt issuance fees impact interest rate hedges percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related table contents notes consolidated financial statements continued sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price specified prospectus change control triggering event occurs certain circumstances defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase september scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering approximately billion interest notes payable semiannually effective interest rate percent senior unsecured notes percent senior unsecured notes incorporates initial discount debt issuance fees percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted redemption date semiannual basis using rate treasury notes comparable remaining terms plus basis points notes basis points notes change control triggering event occurs certain circumstances defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase scheringplough used net proceeds issuance senior unsecured notes fund portion purchase price obs acquisition see note acquisition november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering billion interest notes payable semiannually subject rate adjustment follows rating assigned particular series notes either moodys investors service inc moodys standard poors rating services sp changes rating set forth interest rate payable series notes initial interest rate percent notes due percent notes due plus additional interest rate set forth moodys sp additional interest rate moodys rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade either moodys sp respectively notes subsequently rated baa moodys bbb sp table contents notes consolidated financial statements continued upon issuance notes rated moodys sp july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december resulting percent interest rate payable notes due percent interest rate payable notes due december notes rated baa moodys sp senior unsecured notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes term loan october scheringplough entered fiveyear senior unsecured eurodenominated term loan facility syndicate banks october scheringplough drew euro billion billion term loan fund portion purchase price obs acquisition see note acquisition additional information term loan floating interest rate weighted average rates respectively requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired process research development connection acquisition consummated closing term loan term loan also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets scheringplough made early principal repayments euro million prepayment penalty incurred relating principal repayments addition scheringploughs international subsidiaries approximately million available unused lines credit uncommitted various financial institutions december aggregate amount maturities aggregate amount maturities longterm debt december next five years thereafter follows th ereafter dollars millions longterm debt credit facilities august scheringplough entered billion revolving credit agreement syndicate banks terminated billion credit facility mature may credit facility floating interest rate matures august requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing credit facility credit facility also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated table contents notes consolidated financial statements continued net tangible assets credit line available general corporate purposes considered support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december borrowings outstanding facility commitments total rent expense amounted million million million respectively future annual minimum rental commitments next five years noncancelable operating leases december follows million million million million million aggregate minimum lease obligations million due thereafter december scheringplough commitments totaling million million related capital expenditures made respectively financial instruments sfas requires derivatives recorded balance sheets fair value addition statement also requires effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized statements consolidated operations occur risks policy objectives scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes currently scheringplough deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments limited basis scheringplough hedge selective foreign currency risks derivatives scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide natural level protection adverse changes exchange rates furthermore risk adverse exchange rate change somewhat mitigated fact scheringploughs international operations widespread scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency translation foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options mitigate exposure event significant strengthening euro compared us dollar scheringplough purchased options aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accordingly gain derivatives recognized statement consolidated operations derivatives shortterm trading nature hedge specific financing investment transaction accordingly cash impacts derivatives classified operating cash table contents notes consolidated financial statements continued flows statement consolidated cash flows see note incomeexpense net december open foreign currency option contracts scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt cash flows related interest rate swaps classified operating cash flows statement consolidated cash flows see note expenseincome net december open interest rate swaps scheringplough mitigates credit risk derivative instruments dealing counterparties considered high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instruments manner generate trading profits scheringplough classifies cash flows derivatives accounted hedges category item hedged fair value financial instruments table presents carrying values estimated fair values certain scheringploughs financial instruments december estimated fair values determined based market prices available dealer quotes carrying values financial instruments including cash cash equivalents approximated estimated fair values december carrying estimated carrying estimated value fair value value fair value dollars millions assets shortterm investments longterm investments liabilities shortterm borrowings current portion longterm debt longterm debt longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held non qualified trusts fund longterm employee benefit obligations longterm employee benefit obligations included liabilities consolidated balance sheets assets used fund related employee benefit obligations table contents notes consolidated financial statements continued fair value measurements scheringploughs consolidated balance sheet december includes following assets liabilities measured fair value recurring basis q uoted prices active markets total identical significant significant fair value assets observable unobservable december liabilities inputs inputs level level level dollars millions assets securities held employee compensation total assets liabilities foreign currency exchange contract total liabilities majority scheringploughs assets liabilities measured fair value recurring basis measured using unadjusted quoted prices active markets identical items level inputs multiplied number units held balance sheet date december assets liabilities fair values measured using significant observable inputs level include measurements using quoted prices identical items markets active measurements using inputs derived principally corroborated observable market data shareholders equity preferred shares december scheringplough authorized shares preferred stock consists preferred shares designated percent mandatory convertible preferred stock preferred shares whose designations yet determined december shares percent mandatory convertible preferred stock issued outstanding mandatory convertible preferred stock august scheringplough issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale preferred stock fund portion purchase price obs acquisition see note acquisition additional information share preferred stock automatically convert common shares scheringplough depending average closing price scheringploughs common shares trading day period ending third trading day prior mandatory conversion date august defined prospectus preferred shareholders may elect convert time prior august minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price scheringploughs common shares exceeds least trading days within period consecutive trading days scheringplough may elect cause conversion less table contents notes consolidated financial statements continued preferred stock outstanding minimum conversion ratio common shares share preferred stock shares liquidation preference per share plus amount equal sum accrued cumulated unpaid dividends preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent scheringplough legally permitted pay dividends board directors declares dividend payable scheringplough pay dividends dividend payment date dividend payment dates february may august november year first dividend paid november mandatory convertible preferred stock year ended december shares percent mandatory convertible preferred stock issued august preferred stock converted shares scheringplough common stock following conversion shares preferred stock resumed status authorized unissued preferred stock undesignated series available future issuance equity issuance treasury shares august scheringplough issued common shares treasury shares per share net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale common shares fund portion purchase price obs acquisition see note acquisition additional information summary treasury share transactions years ended december follows shares millions share balance january issuance common shares stock incentive plans activities share balance december included treasury share balance million shares acquired subsidiary scheringplough open market purchase program shares considered treasury shares new jersey law however like treasury shares may voted considered outstanding shares determining necessary votes approve matter submitted stockholder vote subsidiary receive dividends shares effective september board directors scheringplough adopted amended restated certificate incorporation reflecting automatic conversion preferred stock issued shares common stock september terms preferred stock insurance coverage scheringplough maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly scheringplough selfinsures substantially risk relates products liability availability commercial insurance become restrictive scheringplough continually assesses best way provide insurance needs table contents notes consolidated financial statements continued segment information scheringplough three reportable segments prescription pharmaceuticals animal health consumer health care segment sales profitloss data follow consistent scheringploughs current management reporting structure prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products animal health segment discovers develops manufactures markets animal health products consumer health care segment develops manufactures markets overthecounter foot care sun care products primarily us net sales major product segment dollars millions prescription pharmaceuticals remicade nasonex temodar pegintron clarinexaerius follistimpuregon nuvaring claritin rx avelox integrilin caelyx rebetol zemuron remeron intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidated net sales products acquired obs acquisition november table contents notes consolidated financial statements continued net sales geographic area dollars millions united states europe canada latin america asia pacific consolidated net sales scheringplough subsidiaries countries outside us net sales presented geographic area scheringploughs customers located following foreign countries accounted percent consolidated net sales past three years consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions total international net sales france japan germany canada net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions mckesson corporation cardinal health profitloss segment yea r ended decem b er dollars millions prescription pharmaceuticals animal health consumer health care corporate including net interest expenseincome million million million respectively consolidated profitloss tax cumulative effect change accounting principle table contents notes consolidated financial statements continued prescription pharmaceuticals segments profit includes charges arising purchase accounting items million animal health segments profit includes charges arising purchase accounting items million prescription pharmaceuticals segments loss includes billion purchase accounting items including acquired inprocess research development billion animal health segments loss includes million purchase accounting items including acquired inprocess research development million profits animal health segment include gain sale certain animal health products million scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting see note equity income additional information prescription pharmaceuticals segment includes equity income merckscheringplough joint venture corporate includes interest income expense foreign exchange gains losses currency option gains headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies corporate includes special acquisitionrelated charges million comprised million integration related costs million employee termination costs related productivity transformation program includes ongoing integration obs estimated charges relate reportable segments follows prescription pharmaceuticals million animal health million consumer health care million corporate million corporate includes special acquisitionrelated charges million comprised million integration related costs obs acquisition million employee termination costs part integration activities estimated charges relate reportable segments follows prescription pharmaceuticals million animal health million corporate million corporate includes special charges million primarily related changes scheringploughs manufacturing operations us puerto rico announced june related prescription pharmaceuticals segment included cost sales charges approximately million manufacturing streamlining actions primarily related prescription pharmaceuticals segment see note special acquisitionrelated charges manufacturing streamlining additional information supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows p ercentage applicable amount sales dollars millions us nasonex international remicade table contents notes consolidated financial statements continued longlived assets geographic location dollars millions united states netherlands ireland singapore total longlived assets shown geographic location primarily property significant increase longlived assets december due obs acquisition scheringplough disaggregate assets segment basis internal management reporting therefore information presented legal environmental regulatory matters background scheringplough involved various claims investigations legal proceedings scheringplough records liability contingencies probable liability incurred amount reasonably estimated scheringplough adjusts liabilities contingencies reflect current best estimate probable loss minimum liability case may best estimate determinable scheringplough records minimum amount within probable range liability expected insurance recoveries considered determining amounts recorded liabilities environmental related matters scheringplough believes loss contingency reasonably possible rather probable amount loss estimated liability recorded however liability reasonably possible disclosure loss contingency made scheringplough reviews status claims investigations legal proceedings ongoing basis including related insurance coverages time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs consolidated results operations cash flows financial condition except matters discussed remainder note recorded liabilities contingencies december related expenses incurred year ended december material opinion management based advice legal counsel ultimate outcome matters except matters discussed remainder note expected material impact scheringploughs consolidated results operations cash flows financial condition patent matters intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights table contents notes consolidated financial statements continued awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege schering plough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks compensatory damages behalf class court certified shareholder class october notice pendency class action sent members class july february court signed order preliminarily approving settlement agreement proposed settlement agreement scheduled presented final approval hearing june erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain former corporate officers breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anti competitive effects settlements resolved scheringploughs favor alleged class action table contents notes consolidated financial statements continued suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages february special master recommended us district court district new jersey dismiss class action lawsuits summary judgment thirdparty payor actions several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation litigation investigations relating merckscheringplough cholesterol joint venture background january merckscheringplough cholesterol joint venture announced results enhance clinical trial effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia july merckscheringplough cholesterol joint venture announced results seas clinical trial simvastatin ezetimibe aortic stenosis litigation investigations respect matters relating clinical trials ongoing scheringplough cooperating fully various investigations responding requests information scheringplough intends vigorously defend lawsuits filed relating enhance study investigation inquiries february scheringplough joint venture andor joint venture partner merck received number governmental inquiries subject number investigations relating enhance clinical trial include several letters congress including subcommittee oversight investigation house committee energy commerce ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related merckscheringplough cholesterol joint ventures enhance clinical trial also include several subpoenas state officials including state attorneys general requests information us attorneys department justice seeking similar information documents addition scheringplough received letters subcommittee oversight investigations house committee energy commerce seeking certain information documents related seas clinical trial matters scheringplough merck joint venture cooperating investigations responding inquiries january initial release enhance data fda stated would review results enhance trial january fda announced results review fda stated following two years treatment carotid artery thickness increased mm vytorin group mm simvastatin group difference changes carotid artery thickness two groups statistically significant levels ldl cholesterol decreased vytorin group decreased simvastatin group difference reductions ldl cholesterol two groups statistically significant fda also stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk table contents notes consolidated financial statements continued cardiovascular disease fda also stated pending results improveit clinical trial patients stop taking vytorin cholesterol lowering medications talk doctors questions litigation scheringplough continues respond existing new litigation including civil class action lawsuits alleging common law state consumer fraud claims connection scheringploughs sale promotion merckscheringplough jointventure products vytorin zetia several putative shareholder securities class action lawsuits several officers also named defendants alleging false misleading statements omissions scheringplough representatives related timing disclosures concerning enhance results allegedly violation sections b securities exchange act putative shareholder securities class action lawsuit several officers directors also named alleging material misstatements omissions related enhance results offering documents connection scheringploughs securities offerings allegedly violation securities act including section several putative class action suits alleging scheringplough certain officers directors breached fiduciary duties erisa seeking damages amount losses allegedly suffered plans shareholder derivative action alleging board directors breached fiduciary obligations relating timing release enhance results letter behalf single shareholder requesting board directors investigate allegations litigation described warranted bring appropriate legal action behalf scheringplough tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation tried newark district court decision yet rendered scheringploughs tax reserves adequate cover abovementioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection settlement massachusetts investigation commencing new fiveyear term failure comply obligations cia could result financial penalties date scheringplough believes complied obligations matters products liability beginning may number complaints filed various jurisdictions asserting claims organon usa inc organon pharmaceuticals usa inc organon international organon scheringplough corporation arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation venued missouri new jersey state court cases pending states table contents notes consolidated financial statements continued french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court april competitor also requested interim relief portion granted french competition authority december interim relief required scheringploughs french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority january french supreme court confirmed decision french competition authority environmental scheringplough responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law scheringplough alleged potentially responsible party prp scheringplough believes remote time material liability relation sites scheringplough estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps scheringplough records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries company december related statements consolidated operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed index item schedule ii valuation qualifying accounts financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements effective december company adopted statement financial accounting standards employers accounting defined benefit pension postretirement plans discussed note consolidated financial statements effective january company adopted financial accounting standards board interpretation accounting uncertainty income taxes also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries quarterly data unaudited three onths e nded march june september december dollars millions except per share figures net sales cost sales gross margin selling general administrative research development acquired inprocess research development incomeexpense net special charges acquisitionrelated charges equity income cholesterol joint venture incomeloss income taxes income tax expense net incomeloss dividends preferred shares net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions completing final analysis results scheringplough determined certain income tax effects relating accounting purchase obs reflected overstatement income tax expense first three quarterly periods totaling million accordingly scheringplough revised quarterly information included change results reduction income tax expense corresponding increase net income net income available common shareholders along associated per share amounts revisions tax expense net income net income available common shareholders reflected table million first quarter million second quarter million third quarter table contents operating results three month period ended december reflects closing obs acquisition november including impacts purchase accounting accordance sfas business combinations diluted earnings per common share three month period ended september calculated using numerator million arithmetic sum net income available common shareholders million plus dividends million related preferred stock dilutive denominator represents average diluted shares outstanding third quarter see note special acquisitionrelated charges manufacturing changes consolidated financial statements additional information relating special acquisitionrelated charges scheringploughs approximate number holders record common shares january item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated scheringploughs disclosure controls procedures end period covered k concluded scheringploughs disclosure controls procedures effective also concluded changes scheringploughs internal control financial reporting occurred scheringploughs recent fiscal quarter materially affected reasonably likely materially affect scheringploughs internal control financial reporting part changing business environment scheringplough operates scheringplough replacing upgrading number information systems commencing first quarter integrating organon biosciences nv human animal health businesses overall integration process ongoing several years managements report internal control financial reporting management scheringplough corporation responsible establishing maintaining adequate internal control financial reporting scheringploughs internal control system designed provide reasonable assurance scheringploughs management board directors regarding preparation fair presentation published financial statements internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assessed effectiveness scheringploughs internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based assessment management believes december scheringploughs internal control financial reporting effective scheringploughs independent registered public accounting firm deloitte touche llp issued attestation report effectiveness scheringploughs internal control financial reporting report follows item b information applicable table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited internal control financial reporting scheringplough corporation subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule included explanatory paragraph regarding companys adoption statement financial accounting standards employers accounting defined benefit pension postretirement plans financial accounting standards board interpretation accounting uncertainty income taxes deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers corporate governance information concerning directors nominees directors incorporated reference proposal one election directors oneyear term scheringploughs proxy statement annual meeting shareholders information concerning executive officers included part filing caption executive officers registrant information concerning compliance section exchange act incorporated reference section beneficial ownership reporting compliance scheringploughs proxy statement annual meeting shareholders information concerning audit committee audit committee financial expert incorporated reference information audit committee board directors practices audit committee report scheringploughs proxy statement annual meeting shareholders scheringplough adopted code business conduct ethics standards global business practices applicable employees including chief executive officer chief financial officer controller scheringploughs standards global business practices available investor relations section scheringploughs web site wwwscheringploughcom addition written copy materials provided charge writing office corporate secretary scheringplough corporation galloping hill road mail stop k kenilworth new jersey scheringplough intends satisfy disclosure requirement item form k regarding amendment waiver provision standards global business practices posting information web site address specified item executive compensation information concerning executive compensation incorporated reference executive compensation scheringploughs proxy statement annual meeting shareholders item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management incorporated reference stock ownership scheringploughs proxy statement annual meeting shareholders table contents equity compensation plan information following information relates plans equity securities scheringplough may issued employees directors scheringplough plans equity securities may issued nonemployees except stock incentive plan certain stock options may transferable family members employeeoptionee related trusts column column c number securities number securities issued column b remaining available upon exercise future issuance outstanding weightedaverage equity compensation options awards exercise price plans excluding securities plan category warrants rights outstanding options reflected column equity compensation plans approved security holders stock incentive plan na stock incentive plan stock incentive plan stock incentive plan directors compensation plan na na equity compensation plans approved security holders scheringplough ireland approved profit sharing scheme na na organon ireland limited employee share participation scheme na na intervet ireland limited employee share participation scheme na na total plans permit eligible employees work certain scheringplough irish subsidiaries enjoy tax advantages annual bonus amount varying percent percent pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts euro may deferred year employee employees may sell withdraw shares allocated accounts two three years includes shares may issued pursuant outstanding unearned performance awards assuming awards earned maximum levels shares subject awards remain unearned following completion applicable performance period available issuance plan weighted average exercise price set forth column b calculated excluding performance awards described deferred stock units granted plan recipients required pay exercise price receive shares subject awards item certain relationships related transactions director independence information concerning certain relationships related transactions incorporated reference certain transactions procedures related party transactions director independence assessments scheringploughs proxy statement annual meeting shareholders information concerning director independence incorporated reference director independence scheringploughs proxy statement annual meeting shareholders item principal accounting fees services information concerning principal accountant fees services incorporated reference proposal two ratify designation deloitte touche llp audit scheringploughs books accounts scheringploughs proxy statement annual meeting shareholders table contents part iv item exhibits financial statement schedules following documents filed part report financial statements financial statements set forth item k financial statement schedules merckscheringplough cholesterol partnership combined financial statements index p age combined statements net sales contractual expenses years ended december combined balance sheets december combined statements cash flows years ended december combined statements partners capitaldeficit years ended december notes combined financial statements years ended december independent auditors report schedule ii valuation qualifying accounts schedules listed omitted applicable required table contents index exhibits unless otherwise indicated exhibits part commission file number exhibit number description location amended restated certificate incorporation incorporated reference exhibit schering ploughs k filed september b amended restated bylaws incorporated reference exhibit schering ploughs k filed march rights agreement scheringplough incorporated reference exhibit schering bank new york dated june ploughs filed june b form participation rights agreement incorporated reference exhibit schering scheringplough chase manhattan bank ploughs registration statement form national association trustee amendment filed december file ci indenture dated november schering incorporated reference exhibit schering plough bank new york trustee ploughs k filed november cii first supplemental indenture including form note incorporated reference exhibit schering dated november ploughs k filed november ciii second supplemental indenture including form note incorporated reference exhibit schering dated november ploughs k filed november civ global senior note due incorporated reference exhibit civ schering ploughs k year ended december cv global senior note due incorporated reference exhibit cv schering ploughs k year ended december cvi third supplemental indenture including form note incorporated reference exhibit schering dated september ploughs k filed september cvii fourth supplemental indenture including form note incorporated reference exhibit schering dated october ploughs k filed october directors compensation plan amended restated incorporated reference exhibit hiii schering effective june amendments ploughs q period ended september september bi stock incentive plan incorporated reference exhibit schering ploughs q period ended september bii amendment stock incentive plan effective incorporated reference exhibit schering february ploughs q period ended march biii amendment stock incentive plan effective incorporated reference exhibit c schering february ploughs k year ended december c stock incentive plan amended february incorporated reference exhibit schering ploughs k year ended december table contents exhibit number description location stock incentive plan amended restated attached effective january ei letter agreement dated november incorporated reference exhibit eiii schering robert bertolini scheringplough ploughs k year ended december eii employment agreement effective upon change incorporated reference exhibit schering control dated december robert ploughs k filed december bertolini scheringplough corporation eiii amendment letter agreement employment incorporated reference exhibit schering agreement scheringplough corporation ploughs k filed december robert j bertolini dated december eiv employment agreement dated may incorporated reference exhibit schering carrie cox scheringplough ploughs k filed may ev amendment employment agreement incorporated reference exhibit schering scheringplough corporation carrie cox dated ploughs k filed december december evi employment agreement dated april incorporated reference exhibit schering fred hassan scheringplough ploughs k filed april evii amendment employment agreement incorporated reference exhibit schering scheringplough corporation fred hassan dated ploughs k filed december december eviii employment agreement dated december incorporated reference exhibit ev schering thomas p koestler phd schering ploughs k year ended december plough eix amendment employment agreement incorporated reference exhibit schering scheringplough corporation thomas p koestler ploughs k filed december dated december ex letter agreement dated march thomas incorporated reference exhibit schering j sabatino jr scheringplough ploughs q period ended march exi employment agreement effective upon change incorporated reference exhibit eviii control dated april thomas j scheringploughs k year ended december sabatino jr scheringplough exii amendment letter agreement employment incorporated reference exhibit schering agreement scheringplough corporation ploughs k filed december thomas j sabatino jr dated december exiii employment agreement dated december incorporated reference exhibit eviii brent saunders scheringplough scheringploughs k year ended december exiv amendment employment agreement incorporated reference exhibit schering scheringplough corporation brent saunders dated ploughs k filed december december table contents exhibit number description location exv form employment agreement effective upon change attached control scheringplough certain executives new agreements beginning january f operations management team incentive plan incorporated reference exhibit mii schering amended restated effective june ploughs q period ended september g cash longterm incentive plan amended restated incorporated reference exhibit n schering effective january ploughs k year ended december h longterm performance share unit incentive plan incorporated reference exhibit schering amended restated effective january ploughs k year ended december transformational performance contingent shares incorporated reference exhibit p schering program ploughs k year ended december j severance benefit plan amended restated incorporated reference exhibit eviii effective january scheringploughs k year ended december k savings advantage plan amended restated attached effective january l supplemental executive retirement plan amended attached restated january retirement benefits equalization plan amended attached restated january n executive incentive plan amended restated incorporated reference exhibit ai schering october ploughs k year ended december deferred compensation plan amended restated incorporated reference exhibit schering october ploughs k year ended december p amended restated defined contribution trust incorporated reference exhibit aii schering ploughs k year ended december q amended restated serp rabbi trust agreement incorporated reference exhibit g schering ploughs k year ended december r cholesterol governance agreement dated may incorporated reference exhibit schering among scheringplough merck co inc ploughs k dated october parties signatory thereto first amendment cholesterol governance incorporated reference exhibit schering agreement dated december among ploughs k filed october scheringplough merck co inc parties signatory thereto master agreement dated december incorporated reference exhibit schering among scheringplough merck co inc ploughs k filed october parties signatory thereto table contents e xhibi number description location u letter agreement dated april relating consent incorporated reference exhibit schering decree ploughs q period ended march v distribution agreement scheringplough incorporated reference exhibit u schering centocor inc dated april ploughs amended k year ended december filed may w amendment agreement distribution agreement incorporated reference exhibit schering centocor inc development llc ploughs k filed december scheringplough ireland company x share purchase agreement akzo nobel nv incorporated reference exhibit schering scheringplough international cv scheringplough ploughs k filed october corporation computation ratio earnings fixed charges attached standards global business practices covers incorporated reference exhibit schering employees including senior financial officers ploughs k filed september subsidiaries registrant attached consent independent registered public accounting attached firm independent auditors consent attached power attorney attached sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer compensatory plan contract arrangement certain portions exhibit omitted pursuant request confidential treatment nonpublic information filed separately securities exchange commission pursuant rule b securities exchange act amended copies exhibits furnished upon request table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized scheringplough corporation registrant steven h koehler steven h koehler vice president controller duly authorized officer chief accounting officer date february pursuant requirements securities exchange act report signed following persons behalf registrant capacities date indicated fred hassan chairman board chief executive officer fred hassan robert j bertolini executive vice president chief financial officer robert j bertolini steven h koehler vice president controller steven h koehler director hans w becherer director thomas j colligan director c robert kidder director eugene r mcgrath director carl e mundy jr director antonio perez director patricia f russo director jack l stahl director craig b thompson md table contents director kathryn c turner director robert f w van oordt director arthur f weinbach steven h koehler steven h koehler attorneyinfact date february table contents merckscheringplough cholesterol partnership combined statements net sales contractual expenses year ende dec em ber dollars millions net sales cost sales selling general administrative research development income operations accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership combined balance sheets de ce mber dollars millions assets cash cash equivalents accounts receivable net inventories prepaid expenses assets total assets liabilities partners capital rebates payable payable merck net payable scheringplough net accrued expenses liabilities total liabilities commitments contingent liabilities notes partners capital total liabilities partners capital accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership combined statements cash flows yea r ende dece ber dollars millions operating activities income operations adjustments reconcile income operations net cash provided operating activities accounts receivable net inventories prepaid expenses assets rebates payable payable merck scheringplough net accrued expenses liabilities noncash charges net cash provided operating activities financing activities contributions partners distributions partners net cash used financing activities net increasedecrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership combined statements partners capital deficit chering plough merck total dollars millions balance january contributions partners income operations distributions partners balance december contributions partners income operations distributions partners balance december contributions partners income operations distributions partners balance december accompanying notes integral part combined financial statements table contents merckscheringplough cholesterol partnership notes combined financial statements description business basis presentation description business may merck co inc merck scheringplough corporation scheringplough collectively partners entered agreements agreements jointly develop market united states scheringploughs investigational cholesterol absorption inhibitor cai ezetimibe marketed today united states zetia ezetrol countries cholesterol collaboration fixedcombination tablet containing active ingredients montelukast sodium loratadine respiratory collaboration montelukast sodium leukotriene receptor antagonist sold merck singulair loratadine antihistamine sold scheringplough claritin indicated relief symptoms allergic rhinitis respiratory collaboration terminated accordance applicable agreements following receipt notapprovable letter us food drug administration fda fixedcombination tablet cholesterol collaboration formally referred merckscheringplough cholesterol partnership partnership december cholesterol collaboration agreements expanded include countries world except japan cholesterol collaboration agreements provide ezetimibe developed marketed following forms ezetimibe daily cai nonstatin cholesterol reducing medicine used alone coadministered statin drug ezetimibe simvastatin mercks existing zocor statin cholesterol modifying medicine combined one tablet marketed today united states vytorin inegy countries vytorin zetia approved fda july october respectively together products whether marketed vytorin zetia trademarks locally referred cholesterol products cholesterol collaboration agreements partners established jointlyowned limited purpose legal entities based canada united states carry contractual activities partnership countries additional jointlyowned limited purpose legal entity based singapore established rights intellectual property fund oversee research development manufacturing activities cholesterol collaboration markets except latin america subsidiaries merck scheringplough perform marketing activities cholesterol products contract partnership legal entity subsidiary operations collectively referred combined companies latin america partnership sells directly schering plough mercks latin american subsidiaries scheringplough merck compete one another cholesterol market consequently selling promotion distribution activities cholesterol products within latin america included combined companies partnership substantially reliant infrastructures merck scheringplough limited number employees legal entities partnership activities performed employees either merck scheringplough service agreements partnership profits shared partners differing arrangements countries around world generally defined net sales minus agreed upon manufacturing costs expenses incurred partners invoiced partnership direct promotion expenses incurred partners invoiced partnership expenses limited specialty sales force united states incurred partners invoiced partnership certain amounts sales force physician detailing cholesterol products united states puerto rico canada italy administration expenses based percentage cholesterol product net sales invoiced one partners costs expenses incurred table contents merckscheringplough cholesterol partnership notes combined financial statements continued partners contemplated cholesterol collaboration agreements entered subsequently agreed partners agreed upon research development expenses incurred partners invoiced partnership shared equally partners adjusting special allocations nature milestones due one partners partnerships future results operations financial position cash flows may differ materially historical results presented herein risks uncertainties related partnerships business partnerships future operating results cash flows dependent cholesterol products events adversely affect market products could significant impact partnerships results operations cash flows events could include loss patent protection increased costs associated manufacturing increased competition introduction new effective treatments exclusion government reimbursement programs discontinuation removal market product safety reason results future clinical outcomes studies note basis presentation accompanying combined balance sheets combined statements net sales contractual expenses cash flows partners capital deficit include cholesterol respiratory collaboration activities combined companies respiratory collaboration activities primarily pertained clinical development work prelaunch marketing activities spending respiratoryrelated activities ceased following termination collaboration material income operations years presented net sales include net sales cholesterol products sold combined companies expenses include amounts merck scheringplough contractually agreed directly invoice partnership shared contractual profit sharing arrangements partners described accompanying combined financial statements prepared purpose complying certain rules regulations securities exchange commission reflect activities partnership based contractual agreements partners combined financial statements include expenses agreed partners shared included calculation profits contractual agreements partnership intended complete presentation costs expenses would incurred standalone pharmaceutical company discovery development manufacture distribution marketing pharmaceutical products cholesterol collaboration agreements certain activities charged partnership partners based contractually agreed upon allocations partnerincurred expenses described opinion management allocations expenses described made basis reasonably reflects actual level support provided expenses expenses partners reflected separate consolidated financial statements described profit sharing arrangements cholesterol collaboration agreements provide certain partner incurred costs expenses invoiced partnership partners therefore become part profit sharing calculation following paragraphs list typical categories costs expenses generally incurred discovery development manufacture distribution marketing cholesterol products provide description costs expenses treated accompanying combined statements net sales contractual expenses determining profits contractual agreements manufacturing costs expenses contractually agreed upon manufacturing plant costs expenses incurred partners related manufacture cholesterol products included cost sales accompanying combined statements net sales contractual expenses including table contents merckscheringplough cholesterol partnership notes combined financial statements continued direct production costs certain production variances expenses plant services administration warehousing distribution materials management technical services quality control asset utilization manufacturing costs expenses incurred partners agreed included determination profits contractual agreements invoiced partnership therefore excluded accompanying combined financial statements costs expenses include limited yield gains losses excess jointly agreed upon yield rates excessidle capacity manufacturing plant assets direct promotion expenses direct promotion represents direct identifiable outofpocket expenses incurred partners behalf partnership including limited contractually agreed upon expenses related market research detailing aids agency fees directtoconsumer advertising meetings symposia trade programs launch meetings special sales force incentive programs product samples contractually agreed upon expenses included selling general administrative accompanying combined statements net sales contractual expenses promotion expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements selling expenses united states canada puerto rico markets outside united states primarily italy general sales forces partners provide majority physician detail activity agreed upon cost included selling general administrative accompanying combined statements net sales contractual expenses addition agreed upon costs limited specialty sales force united states market calls opinion leaders field cholesterol medicine also included selling general administrative selling expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements expenses include total costs general sales forces partners detailing cholesterol products countries united states canada puerto rico italy administrative expenses administrative support primarily provided one partners contractually agreed upon expenses support determined based percentage net sales cholesterol products amounts included selling general administrative accompanying combined statements net sales contractual expenses selected contractually agreed upon direct costs employees partners support services outofpocket expenses incurred partners behalf partnership also included selling general administrative expenses incurred partners agreed included determination profits contractual agreements excluded accompanying combined financial statements expenses include limited certain us managed care services partners subsidiary management international markets indirect expenses corporate overhead interest research development rd expenses rd activities performed partners agreed upon costs expenses invoiced partnership agreed upon expenses generally represent allocation partners estimate full time equivalents devoted preclinical postmarketing clinical development regulatory activities include grants thirdparty expenses contractually agreed upon allocated costs included research development accompanying combined statements net sales contractual expenses rd costs incurred partners jointly agreed upon excluded accompanying combined financial statements table contents merckscheringplough cholesterol partnership notes combined financial statements continued summary significant accounting policies principles combination accompanying combined balance sheets combined statements net sales contractual expenses cash flows partners capital deficit include cholesterol respiratory collaboration activities combined companies interpartnership balances profits eliminated use estimates combined financial statements prepared based contractual agreements partners described include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns government managed care rebates uncertainty inherent estimates actual results may differ estimates foreign currency translation net assets partnerships foreign operations translated us dollars current exchange rates us dollar effects arising translating net assets operations included partners capital significant cash cash equivalents cash cash equivalents primarily consist highly liquid money market instruments original maturities less three months partnership changed certain cash management practices increasing amount cash held partnership partnerships cash primarily invested highly liquid money market instruments used fund trade obligations coming due month distributions partners interest income earned cash cash equivalents reported reduction selling general administrative accompanying combined statements net sales contractual expenses amounted million million million respectively inventories substantially inventories valued lower first first cost market intangible assets intangible assets consist licenses trademarks trade names owned partnership intangible assets recorded partners historical cost date contribution nominal value revenue recognition rebates returns allowances revenues sales cholesterol products recognized title risk loss pass customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations net sales vytorininegy zetiaezetrol years ended december follows millions vytorininegy zetiaezetrol total united states sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesale purchaser known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions sales recorded net provisions table contents merckscheringplough cholesterol partnership notes combined financial statements continued sales discounts returns reliable estimates made time sale reserves chargebacks discounts returns allowances reflected direct reduction accounts receivable amounted million million december respectively accruals rebates reflected rebates payable shown separately combined balance sheets income taxes generally taxable income losses partnership allocated partners included partners income tax return states jurisdictions partnership subject income tax included combined financial statements shared partners except income taxes significant combined financial statements provision made federal foreign state income taxes december partnership million deferred tax assets comprised solely net operating loss carryforwards nols generated branch legal entity partnership nols expire carry full valuation allowance january partnership adopted financial accounting standards board interpretation accounting uncertainty income taxes fin adoption fin impact partnerships financial statements concentrations credit risk segment information partnerships concentrations credit risk consist primarily accounts receivable partnership normally require collateral security support credit sales bad debts years ended december minimal december three customers represented accounts receivable net three customers accounted net sales shown table pe r cent f ne sales mckesson drug company cardinal health inc amerisourcebergen corp partnership derived approximately combined net sales united states respectively termination respiratory collaboration respiratory collaboration terminated accordance applicable agreements following receipt approvable letter fda proposed montelukastloratadine combination tablet result termination scheringplough received million incremental allocations partnership profits except allocation certain profits termination impact cholesterol collaboration inventories inventories december consisted millions finished goods raw materials work process total partnership entered longterm agreements partners supply active pharmaceutical ingredients api formulation packaging cholesterol products table contents merckscheringplough cholesterol partnership notes combined financial statements continued agreed upon cost connection supply agreements partnership entered capacity agreements partnership committed take specified annual minimum supply api formulated tablets pay penalty capacity agreements effect period seven years following first full year production one partners expire beginning partnership payment obligation capacity agreements december related party transactions partnership receives substantially goods services including pharmaceutical product manufacturing services sales force services administrative services rd services partners partnership net payable merck scheringplough services million million respectively december million million respectively december selling general administrative expense includes contractually defined costs physician detailing provided scheringplough merck million million respectively million million respectively million million respectively expenses necessarily reflective actual cost partners sales efforts countries amounts contractually defined included amounts million million million respectively relating contractually defined costs physician detailing italy amounts invoiced paid partnership partners component profit sharing calculation cost sales selling general administrative expense also include contractually defined costs distribution administrative services provided merck scheringplough million million million respectively amounts necessarily reflective actual costs distribution administrative services partnership also sells cholesterol products directly partners principally merck scheringplough affiliates latin america latin america partners compete one another cholesterol market merck scheringplough purchase cholesterol products partnership sell directly third parties sales partners included net sales invoiced price accompanying combined statements net sales contractual expenses totaled million million million respectively legal matters partnership may become party claims legal proceedings nature considered normal business including product liability intellectual property partnership records liability connection matters probable liability incurred amount reasonably estimated legal costs associated litigation investigation activities expensed incurred partnership maintains insurance coverage deductibles selfinsurance management believes cost beneficial partnership selfinsures risk relates product liability accrues estimate product liability claims incurred reported february scheringplough received notice glenmark pharmaceuticals inc usa glenmark generic pharmaceutical company indicating filed abbreviated new drug application anda generic form zetia challenging us patents listed zetia march scheringplough partnership filed patent infringement suit glenmark parent company lawsuit automatically stays fda approval glenmarks anda earlier october adverse court decision scheringplough partnership intend vigorously defend patents believe valid infringement generic companies attempting table contents merckscheringplough cholesterol partnership notes combined financial statements continued market products prior expiration dates patents litigation assurances outcomes adverse could result significantly shortened periods exclusivity january partners announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary end point change thickness carotid artery walls two years measured ultrasound also significant differences treatment ezetimibesimvastatin simvastatin four prespecified key secondary end points percent patients manifesting regression average carotid artery intimamedia thickness ca imt proportion patients developing new carotid artery plaques mm changes average maximum ca imt changes average ca imt plus average common femoral artery imt enhance compared simvastatin alone ezetimibesimvastatin significantly lowered ldl bad cholesterol well triglycerides creactive protein crp ezetimibesimvastatin indicated reduction crp enhance study overall safety profile ezetimibesimvastatin generally consistent product label enhance study designed powered evaluate cardiovascular clinical events improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established march results enhance reported annual scientific session american college cardiology january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease fda also stated based current available data patients stop taking vytorin cholesterol lowering medications talk doctor questions vytorin zetia enhance trial july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events also significant difference key secondary end point aortic valve events however reduction group patients taking vytorin compared placebo key secondary end point ischemic cardiovascular events vytorin indicated treatment aortic stenosis incremental benefit vytorin cardiovascular morbidity mortality demonstrated simvastatin established study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems partners partnership believe cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial announcement fda also cited interim data two large ongoing cardiovascular trials vytorin study heart renal protection sharp improveit clinical trials increased risk cancer combination table contents merckscheringplough cholesterol partnership notes combined financial statements continued simvastatin plus ezetimibe sharp trial expected completed improveit trial scheduled completion around fda determined time findings seas trial plus interim data ongoing trials prompt patients stop taking vytorin cholesterol lowering drug partners partnership committed working regulatory agencies evaluate available data interpretations data believe changes clinical use vytorin warranted previously disclosed since december merck scheringplough received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers merck scheringplough addition since august partners received three additional letters oi including one dated february seeking certain information documents related seas clinical trial also previously disclosed partners partnership received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents addition partners partnership received five civil investigative demands cids multistate group state attorneys general jointly investigating whether violations state consumer protection laws occurred marketing vytorin finally september merck scheringplough received letter civil division us department justice doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs partners partnership cooperating investigations responding inquiries addition partners partnership become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection partnerships sale promotion vytorin zetia certain lawsuits allege personal injuries andor seek medical monitoring actions filed transferred federal court coordinated multidistrict litigation us district court district court new jersey district judge dennis cavanaugh parties presently engaged motions practice briefing feasible predict outcome investigations lawsuits arising enhance seas clinical trials unfavorable outcomes could significant adverse effect partnerships financial position results operations cash flows table contents independent auditors report partners merckscheringplough cholesterol partnership audited accompanying combined balance sheets merckscheringplough cholesterol partnership partnership december described note related combined statements net sales contractual expenses partners capital deficit cash flows described note three years period ended december financial statements responsibility management partnership merck co inc scheringplough corporation responsibility express opinion financial statements based audits conducted audits accordance generally accepted auditing standards established auditing standards board united states accordance auditing standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement partnership required engaged perform audit internal control financial reporting audits included consideration internal control financial reporting basis designing audit procedures appropriate circumstances purpose expressing opinion effectiveness partnerships internal control financial reporting accordingly express opinion audit also includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion accompanying statements prepared purpose complying certain rules regulations securities exchange commission described note intended complete presentation financial position results operations cash flows activities standalone pharmaceutical company involved discovery development manufacture distribution marketing pharmaceutical products opinion financial statements referred present fairly material respects combined financial position merckscheringplough cholesterol partnership described note december combined results net sales contractual expenses combined cash flows described note three years period ended december conformity accounting principles generally accepted united states america deloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries schedule ii valuation qualifying accounts years ended december valuation qualifying accounts deducted assets apply allowances accounts receivable serve r eserve r eserve doubtful cash claims accounts discounts total dollars millions balance beginning year additions charged costs expenses deductions reserves effects foreign exchange balance end year balance beginning year obs reserves acquired november additions charged costs expenses deductions reserves effects foreign exchange balance end year balance beginning year additions charged costs expenses deductions reserves effects foreign exchange balance end year